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ABSTRACT

Calcium/Calmodulin-Dependent Protein Kinase IIβ (CaMKIIβ): A Regulator of
Oligodendrocyte Maturation and Myelination
By Christopher Thomas Waggener
A dissertation submitted in partial fulfillment of the requirements for the degree of
Doctor of Philosophy at Virginia Commonwealth University
Virginia Commonwealth University
Advisor: Babette Fuss, Ph.D., Professor, Department of Anatomy and
Neurobiology
Oligodendrocytes are cells located in the central nervous system (CNS)
that are responsible for the production of the lipid rich membrane, myelin. Myelin
and the process of making and wrapping myelin around an axon (also known as
myelination) are critical for normal development since they ensure proper signal
conduction in the vertebrate CNS. The loss or damage of this myelin, which is
typically associated with the demyelinating disease multiple sclerosis (MS), is
associated with improper axonal protection along with disrupted nerve signaling
which can lead to a variety of different debilitating phenotypic responses. It has
been shown that there are MS lesions in which oligodendrocyte progenitors are
present. However, while these cells are thought to possess the intrinsic ability to
myelinate, they do not efficiently mature and/or repair the myelin sheath within
the MS lesion. The reasons for this block in differentiation are currently not fully
understood. A critical and thorough understanding of oligodendrocyte
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development provides the foundation needed for future research to potentially
provide therapeutic targets for stimulating proper maturation and efficient
remyelination from the oligodendrocyte progenitors that are present within the
MS brain.
In the search for regulators of oligodendrocyte development and potential
therapeutic targets, the data generated as part of my thesis provided evidence
that CaMKII (more specifically CaMKIIβ) is a regulator of oligodendrocyte
myelination and maturation. Using pharmacological inhibitors or siRNA-mediated
knockdown of this protein resulted in improper formation of the oligodendrocyte
process network. Interestingly, siRNA-mediated knockdown of CaMKIIβ
appeared to play no noticeable role in the genetic regulation of specific
oligodendrocyte developmental markers. Furthermore, an overall reduction of
the thickness of the compact myelin was observed in the ventral spinal cord of
CaMKIIβ knockout mice. These findings emphasize the importance of CaMKIIβ
in oligodendrocyte myelination and maturation.
To further investigate CaMKIIβ’s role in the regulation of CNS myelination,
the effect of glutamate signaling on CaMKIIβ and in particular its actin binding
site were assessed. These data showed that signaling via glutamate transporters
promote an increase of process network in oligodendrocytes. This effect was
associated with a transient increase in intracellular calcium concentration and a
change in the phosphorylation of at least one serine residue present within
CaMKIIβ’s actin binding site. Changes in phosphorylation of CaMKIIβ’s actin
binding site suggested that CaMKIIβ detaches from filamentous F-actin and
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allows for remodeling of the oligodendrocyte’s actin cytoskeleton. This was
demonstrated by overexpressing CaMKIIβ actin binding mutant constructs to
alter phosphorylation of serine residues to either always allow actin binding
(CaMKIIβallA) or never allow actin binding (CaMKIIβallD). The overexpression of
CaMKIIβallD alone demonstrated a decrease in the process network of
oligodendrocytes and inhibited the effect of glutamate on the process network. In
contrast, the overexpression of CaMKIIβallA and CaMKIIβWT alone showed normal
process network formation along with a significant increase in the process
network after stimulation of glutamate. The above data strongly suggest that
there is a significant relationship between sodium dependent glutamate
transporters/CaMKIIβ activation and the oligodendrocyte cytoskeleton in the role
of regulation of oligodendrocyte differentiation and CNS myelination.
The data presented in this dissertation provides overwhelming evidence
that CaMKIIβ plays a significant role in the proper formation of the
oligodendrocyte complex process network and myelination. CaMKIIβ’s
relationship with glutamate and the actin cytoskeleton could lay the foundation for
future research not only for the signaling of oligodendrocyte process formation
and remyelination but also for future targets for MS therapies.

CHAPTER 1
Introduction to Oligodendrocyte Biology and CaMKIIβ
Myelin and its functional significance
The myelin membrane is the most prominent membrane structure in the
vertebrate nervous system. Myelin is a lipid rich multilamellar membrane that
surrounds axons in a segmental fashion. Oligodendrocytes in the central
nervous system and Schwann cells in the peripheral nervous system are the
cells that are responsible for producing the myelin membrane. Myelin was
originally named by Rudolf Virchow in the mid 1850’s (Baumann and Pham-Dinh,
2001); however, oligodendrocytes were discovered by Rio Hortega almost 70
years later in 1921(Helmut Kettenmann, 2005). The myelin membrane is highly
insulative and has a low water content. Myelin has a unique segmental
morphology that structurally allows for gaps in between the myelin segments.
These gaps (also known as nodes of Ranvier) allow for fast and efficient
propagation of nerve impulses called action potentials. This fast propagation of
action potentials is due to a process named saltatory conduction, which allows
for faster conductions over long distances and reliable signal transfer in smaller
diameter axons (Baumann and Pham-Dinh, 2001).
Myelin was one of the later structures of the nervous system to evolve
(Baumann and Pham-Dinh, 2001, Hartline and Colman, 2007). Evolutionary need
for fast conduction of nerve fibers stems from the demand for animals to make
quick decisions to avoid prey (Hartline and Colman, 2007). There are certain
physiological properties that allow for increased speed of conduction. Increasing
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the size of the axon decreases the overall resistance of the electrical signal and
allows for faster conduction. This option is not practical in mammals, as nerve
fibers would have to be extremely large in proportion to the their body size and
space requirements for the type of conduction speed that mammals require.
Insulating the axon with a thick lipid myelin membrane increases the resistance
of the electrical field in the longitudinal axis of the axon from the outside of the
membrane and decreases the transverse capacitance between the inside and
the outside nerve fiber (Hartline and Colman, 2007). By insulating the axon with
myelin, sodium channels are clustered at the nodes of Ranvier while there are no
action potentials generated along the segmental myelin sheath (internode). The
clusters of sodium channels combined with the insulation of the myelin sheath
greatly increase the conduction velocity of action potentials while keeping the
axon diameter reasonably small (Baumann and Pham-Dinh, 2001, Helmut
Kettenmann, 2005).
The importance of myelin has become evident not only in pathologies (or
experimental paradigms) where it is not formed properly during development but
also under conditions in which it is destructed such as in the demyelinating
disease multiple sclerosis (MS) (Baumann and Pham-Dinh, 2001).

Multiple sclerosis (MS), the major demyelinating disease in humans
Understanding oligodendrocyte development is essential to gain more
knowledge not only in the basic developmental process of myelination but also to
treat diseases and disorders that affect oligodendrocytes and/or myelin. One of
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the most studied demyelinating diseases is multiple sclerosis (MS). Currently
there is no cure for the disease and no treatment for stimulating remyelination by
oligodendrocytes and/or their progenitors. MS affects 2.1 million people
worldwide (Multiple Sclerosis Society 2013). There are over 400,000 diagnosed
cases in the United States alone with more than 200 new cases diagnosed a
day. The most common ages of diagnosis of MS is between the ages of 20 to 50
years of age. However, over the past few years, there has been an increase in
the diagnosis of pediatric cases (Fox et al., 2006b, Yeh et al., 2009). MS
presents as single or multiple lesions anywhere in the brain and results in
symptoms that can range from a single neurological deficit to multiple
neurological deficits (Fox et al., 2006b).
The cause of MS is still unknown; however, there are genetic and
environmental factors that are thought to play a role in the development of the
disease (Hauser and Oksenberg, 2006). One of the current environmental factors
that could contribute to the disease is a vitamin D deficiency. An epidemiological
study showed that MS cases tend to occur less frequently in populations of
people who live closer to the equator. Researchers theorize that people living
closer to the equator tend to have more sun exposure than those living in colder
climates farther away from the equator (Freedman et al., 2000).
The genetic factors of MS are widely unknown and have not been strictly
linked to heredity. However, an individual is much more at risk of developing MS
than the general population if that individual has had a first-degree relative
(parent or sibling) with MS . Furthermore, some researchers believe that
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individuals are born with a genetic predisposition that makes them more sensitive
to environmental agents that can cause the disease (Multiple Sclerosis Society
2013). All in all, there are many theories for the environmental and genetic
causes for MS but researchers have not been able to pinpoint specific reasons
why people develop MS.
MS is a complicated disease; currently there are 4 different disease
courses with varying amounts of severity. The most common type of MS is
relapsing-remitting with 85% of patients being diagnosed with this form of the
disease. Relapsing-remitting MS is characterized by bouts of MS attacks with
symptoms included but not limited to: sensory symptoms (numbness and
tingling), motor symptoms (weakness and spasticity), coordination abnormalities,
vision difficulties, bladder dysfunction, and fatigue; followed by periods of
recovery (Fox et al., 2006b, Comabella and Martin, 2007). The second form of
the disease is primary progressive. This form of the disease has been
characterized by slow but gradually progressive neurologic symptoms from the
onset with no time points of recovery. The primary progressive type is seen in
about 10% of the population with MS (Fox et al., 2006b). Secondary progressive
is the third form of MS that is seen in about 50% of the MS population that first
exhibits the relapsing-remitting form of MS (Fox et al., 2006b). Secondary
progressive MS is characterized by a continuous worsening of neurological
deficits with differing amounts of severity over time. Lastly the most rare form of
MS is progressive relapsing. With only 5% occurrence in the population,
progressive relapsing MS is characterized by steadily worsening disease from
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the beginning but with clear bouts of more severe neurological symptoms. Times
of remissions are seen by some but not all of the patients experiencing this form
of MS (Multiple Sclerosis Society 2013). Therefore, classifying MS can be
difficult, especially given the varying symptoms and degrees of severity
(Comabella and Martin, 2007).
Although the cause of MS is unknown, much progress has been made in
understanding the pathology of MS. Since MS is classified as an autoimmune
disease, inflammation is often associated with MS lesions and potentially plays a
role in the damaging of oligodendrocytes. Whether or not the axon is affected by
the inflammation or the physical loss of myelin is still under debate in the field.
Current therapies are treating this inflammation and attenuating or lessening the
relapsing portion of the disease. However, the loss of myelin and axonal damage
still continues and is not treated by the current therapies on the market for MS
patients.
Because there are no current therapies to correct or aid in the
remyelination of axons by oligodendrocytes in MS lesions, the focus of this
dissertation is on understanding oligodendrocyte development and myelination.
This information is important because it is believed that the repair of the myelin
sheath follows the same concepts as the generation of the myelin sheath during
normal development. By researching oligodendrocyte development, researchers
can identify oligodendrocytes found in MS lesions and use this information to
target potential remyelination therapies. The oligodendrocytes in MS lesions are
immature and lack the ability to remyelinate (Chang et al., 2002). The lack of
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differentiation in oligodendrocytes present in the MS lesion leads to inhibition of
proper remyelination. This could be due to an altered local environment and
altered signals (Chang et al., 2002,Colognato, 2011 #368, Lafrenaye and Fuss,
2010). Although some of these cells remyelinate axons, this remyelination is
insufficient (Goldschmidt et al., 2009, Bradl and Lassmann, 2010, Emery, 2010).
Understanding oligodendrocyte development and myelination can provide
a wealth of information that could lead to potential therapies to repair the
damaged/absent myelin in MS and possibly also in other diseases displaying
pathological features of demyelination (such as leukodystrophies, neuromyelitis
optica, transverse myelitis, and optic neuritis) (Keyoung and Goldman, 2007,
Goldman et al., 2012). One option for a potential therapy is stem cell
replacement. Exogenous stem cell transplantation studies have shown promising
results. However, current research resulted in a shift towards pharmacologicallybased therapies. Pharmacologically-based therapies target the endogenous
regenerative processes of oligodendrocyte maturation and myelination. This
research has focused on the changes not only within the cell but also on changes
within the environment around the cells to a younger more plastic environment to
enhance remyelination. (Lindvall and Kokaia, 2006, Zawadzka et al., 2010,
Ruckh et al., 2012, Stoffels et al., 2013). Studies have shown that by replacing
macrophages and blood factors from younger animals into older animals that
have demyelinating lesions, remyelination by the endogenous cells was achieved
(Lindvall and Kokaia, 2006, Zawadzka et al., 2010, Ruckh et al., 2012, Stoffels et
al., 2013). This result is significant because it shows that less plasticity in the
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cells and local environment is observed in older animals. These cells, however,
have the innate ability to remyelinate if prompted by the new altered local
environment around them. This research and other research into oligodendrocyte
development are leading to a better understanding of the molecular mechanisms
that promote oligodendrocyte differentiation during development that have the
potential to reveal novel targets for designing remyelinating therapies. This
research is also important because there are no current therapies that address
the issue of remyelination available for patients today.

Oligodendrocyte specification
Since the discovery of oligodendrocytes, their origins in the brain and spinal
cord have been highly debated. Recent in vivo studies using transgenic mouse
models to track the origins of oligodendrocytes have, for the most part, provided
much insight into the origins of oligodendrocytes. The majority of this research
has, however, focused on the spinal cord and only very recently has begun to
explore the origins of oligodendrocytes in the brain (Richardson et al., 2006)
As the brain develops from its early embryonic form to its more mature
form, it develops layers and zones of cell initiation and proliferation. These zones
of development as well as all of the brain and spinal cord are of neuroectodermal
origin. Each zone comprises and produces distinct cell types and cell
morphologies (Pringle et al., 1996, Woodruff et al., 2001, Brazel et al., 2003,
Marshall et al., 2003, Helmut Kettenmann, 2005, Richardson et al., 2006).
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Neurons and some astrocytes originate from the ventricular zone of the
brain, which is the first cell proliferative area to develop. The ventricular zone of
the brain is a pseudostratified epithelial-like tissue that consists of
neuroectodermal tissue (Helmut Kettenmann, 2005). During embryonic
development, an area of tissue distal to the ventricular zone becomes highly
proliferative and begins to thicken. This new proliferative area of the brain is
known as the subventricular zone (Brazel et al., 2003). Since the cells within the
ventricular zone lose their proliferative capability by birth (P0) in the mouse, the
cells leave the ventricular zone and will eventually diminish into a thin wall of
ependymal cells. In contrast, the subventricular zone remains actively
proliferative early postnatally (Brazel et al., 2003). In the cortex, cortical
progenitors follow a developmental sequence of neuronal development, then
astrocyte development, and lastly oligodendrocyte development. The generation
of each of these cell types occurs in a temporally distinct yet overlapping pattern
(Spassky et al., 1998, Spassky et al., 2000, Sauvageot and Stiles, 2002).
From studies in the rodent system, oligodendrocyte progenitors are thought
to be derived from discrete locations in the brain and spinal cord (Miller, 1996,
Woodruff et al., 2001, Richardson et al., 2006). Research suggests that
oligodendrocyte progenitor cells arise from the ventricular zone of the spinal cord
and the subventricular zone of the developing brain (Privat and Leblond, 1972,
Levison et al., 1993, Brazel et al., 2003, Marshall et al., 2003, Helmut
Kettenmann, 2005, Baracskay et al., 2007). The majority of oligodendrocyte
progenitor cells arise from this subventral region of the neuroaxis (Helmut
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Kettenmann, 2005). Experiments conducted with rat spinal cords showed that
initially most oligodendrocytes have a restricted subventral origination and only
later are derived from more dorsal regions as well.
There are multiple areas along the ventral and dorsal axes of the spinal
cord that produce oligodendrocyte progenitor cells at different time points. The
so-called pMN (motor neuron progenitor) domain of the spinal cord is responsible
for 85 percent of the oligodendrocyte production in the first wave of
oligodendrocyte generations beginning around E12.5 (Richardson et al., 1988,
Pringle and Richardson, 1993, Miller, 1996, Pringle et al., 1996, Woodruff et al.,
2001, Richardson et al., 2006). The second wave of oligodendrocyte production
in the spinal cord is found to originate from more dorsal regions in the area of the
dorsal progenitor domains 3-5 around E15 (Cai et al., 2005, Fogarty et al., 2005,
Vallstedt et al., 2005, Emery, 2010).
Oligodendrocyte progenitor cells in the brain can be found in various
regions of the subventricular zone (Levison and Goldman, 1993, Helmut
Kettenmann, 2005). More specifically, oligodendrocytes originate from the medial
and lateral ganglionic eminences (Woodruff et al., 2001, Brazel et al., 2003, de
Castro and Bribian, 2005, Kessaris et al., 2006, Richardson et al., 2006). These
eminence structures are thought to be transient and are only present during
embryonic development. Data from transgenic fate mapping suggests that
oligodendrocyte progenitor cells migrate from these subventricular structures to
the cortex in several waves (Figure 1.1). Oligodendrocyte progenitor cells of the
first wave are first seen in the SVZ at E12.5 where they then migrate into the
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cortex (Kessaris et al., 2006, Richardson et al., 2006). Oligodendrocytes in and
throughout the entire cortex are observed around E18 (Woodruff et al., 2001,
Kessaris et al., 2006, Richardson et al., 2006).
The second wave of movement from the subventricular zone comes from
the more dorsal region of the lateral and caudal ganglionic eminences (Woodruff
et al., 2001, Brazel et al., 2003, Kessaris et al., 2006, Richardson et al., 2006).
Before E18, the source of oligodendrocyte progenitor cells originate from more
ventral locations. After E18, the contribution of ventral cells decreases and a
second wave of more dorsal locations sends cells to the cortex (Woodruff et al.,
2001, Kessaris et al., 2006, Richardson et al., 2006).
The third wave of migration comes from the dorsolateral subventricular
zone. This zone can be identified through adulthood (Woodruff et al., 2001,
Brazel et al., 2003, Kessaris et al., 2006, Richardson et al., 2006). The later
migration from the dorsolateral subventricular zone starts at P2 of development
(Levison and Goldman, 1993, Brazel et al., 2003). Thus, spatiotemporal
oligodendrocyte specification initially begins in the ventral regions of the brain
and spinal cord and then migrates to dorsal regions as development progresses
(Cai et al., 2005, Fogarty et al., 2005, Vallstedt et al., 2005, Richardson et al.,
2006, Emery, 2010) (Figure 1.1).
From the areas of origin, oligodendrocyte progenitor cells migrate in a
dorsal and lateral pattern in the brain and spinal cord (Levison and Goldman,
1993, Cayre et al., 2009). Dorsally migrating cells not only move in a
dorsolateral pattern but also move radially as well, stopping in white matter areas
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above their original location or moving through the white matter into the cortex
(Cayre et al., 2009) (Figure 1.1).
Unlike developing neurons, oligodendrocyte progenitor cells still proliferate
while undergoing the process of migration. Evidence from real time imaging of
acute brain slices suggests that migration temporarily ceases when mitosis
begins (Zerlin et al., 2004, Cayre et al., 2009). Temporarily stopping migration
explains why oligodendrocyte progenitors can create clonal populations of cells
that colonize multiple levels of white matter and cortex (Zerlin et al., 2004).
Interestingly, the above described ventral dorsal spatiotemporal
oligodendrocyte progenitor cell specification is not seen in the chick embryo.
Chick and quail grafting experiments show that all oligodendrocytes in the avian
cortex are ventrally derived (Richardson et al., 2006). It seems to be that only the
higher order animals are capable of dorsally derived oligodendrocytes
progenitors.
As discussed above, oligodendrocyte progenitors arise from specific
restricted locations and migrate in a controlled fashion throughout the central
nervous system to populate future white matter areas of the brain.

Oligodendrocyte differentiation – changes in gene expression
As described above, oligodendrocyte progenitor cells are first specified in
localized ventricular and subventricular zones in the spinal cord and brain. These
cells then begin a radial dorsolateral migration pattern away from the highly
proliferative zones of origination to populate the entire spinal cord and brain,
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where they differentiate into mature myelinating oligodendrocytes. Specific cell
markers (lipids, proteins, surface antigens, or transcription factors) have been
found to characterize distinct stages of oligodendrocyte differentiation. These
markers have specific functions when it comes to the gene regulatory
mechanisms and protein interactions that allow for the oligodendrocyte to
develop normally. There are several types of signals that regulate
oligodendrocyte development. While there has been considerable debate about
whether in vivo and in vitro models yield the same findings concerning the
oligodendrocyte lineage, much of the signaling properties that have been
characterized in vitro hold true to what naturally occurs in animal systems
(Lazzarini, 2004, Nishiyama et al., 2009). These specific cell markers along with
a change in the cellular morphology allow for proper identification and study of
oligodendrocyte development (Pfeiffer et al., 1993, Baumann and Pham-Dinh,
2001, Bradl and Lassmann, 2010).
Markers of oligodendrocyte development consist of lipids and proteins
expressed by one or more stages of the oligodendrocyte lineage. Olig2 is a
transcription factor that has been implicated in regulating the specification of
oligodendrocyte progenitor cells and remains expressed throughout the lineage
in rodents (Liu et al., 2007). Sox10 is another transcription factor expressed and
regulates development of oligodendrocyte progenitor cells once they become
specified and remains expressed throughout the oligodendrocyte lineage (Liu et
al., 2007). In the rodent model system, one of the early cell surface lipids for
premature oligodendrocytes is identified by the antibody A2B5. This antibody
12

recognizes several gangliosides on the cell surface (Raff et al., 1983, Raff et al.,
1984, Pfeiffer et al., 1993, Baumann and Pham-Dinh, 2001, Baracskay et al.,
2007, Bradl and Lassmann, 2010). This antibody characterizes an early bipolar
or unipolar morphology of an oligodendrocyte progenitor cell and the lipids it
recognizes are downregulated as the cell differentiates into a more mature
oligodendrocyte (Raff et al., 1983, Raff et al., 1984, Pfeiffer et al., 1993,
Baumann and Pham-Dinh, 2001, Baracskay et al., 2007, Bradl and Lassmann,
2010) (Figure 1.2). These A2B5+ oligodendrocyte progenitor cells are highly
migratory and proliferative in the presence of platelet derived growth factor
(PDGF) (Richardson et al., 1988, Gard and Pfeiffer, 1993, Pringle and
Richardson, 1993). In the in vivo system, PDGF is thought to be secreted by
neuronal cell bodies and astrocytes (Richardson et al., 1988, Fruttiger et al.,
2000, Rosenberg et al., 2007) (Figure 1.3). PDGF increases the proliferation and
survival of oligodendrocyte progenitor cells (Hart et al., 1989a, Hart et al.,
1989b). Since PDGF signals to these oligodendrocyte progenitor cells, the
receptor that they express for PDGF is another marker often used to identify
them (Richardson et al., 1988, Gard and Pfeiffer, 1993, Pringle and Richardson,
1993). This receptor is the platelet derived growth factor receptor alpha
(PDGFRα). Basic fibroblast growth factor (bFGF) is a growth factor and mitogen
to which early oligodendrocytes respond (Fok-Seang and Miller, 1994). The
combination of both PDGF and bFGF promotes cell proliferation and inhibits
differentiation (Gard and Pfeiffer, 1993, Pfeiffer et al., 1993).
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As oligodendrocyte development progresses, mitogenic factors wane and
oligodendrocytes are then introduced to the differentiating factor thyroid hormone
(TH). TH and a lack of mitogenic factors are necessary for oligodendrocyte
progenitor cell maturation (Barres et al., 1994, Franco et al., 2008) (Figure 1.3).
As the oligodendrocyte progenitor cells change biochemically, changes in
morphology are occurring simultaneously. Oligodendrocytes become multipolar
and reactive with the mouse monoclonal antibody O4, which binds to an
uncharacterized surface antigen (POA) and sulfatide (Bansal et al., 1989, Bansal
et al., 1992)(Figure 1.2). This seems to be the last point where these O4
expressing cells have proliferative capabilities. From this point on, their
postmigratory stage of life is slowing and will soon end (Warrington and Pfeiffer,
1992).
CNP (2',3'-cyclic nucleotide 3'-phosphodiesterase) is a marker for more
mature, so-called premyelinating oligodendrocytes (Trapp et al., 1988) (Figure
1.2). CNP is a protein that catalyzes 2’,3’-cyclic nucleotides to make
2’nucleotides. In addition to its presence in premyelinating oligodendrocytes, it is
also seen in uncompacted myelin in the paranodal loops (Wells and Sprinkle,
1981, Nave and Trapp, 2008). The biological role of CNP in vivo is not well
understood to date. However, when CNP is overexpressed in mice, premature
and abnormal myelination is observed and when overexpressed in vitro, it
promotes process outgrowth (Lee et al., 2005, Nave and Trapp, 2008). The roles
in CNP regulating the cytoskeleton have been described in the “Oligodendrocyte
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differentiation – changes in actin cytoskeletal organization” section of the
introduction.
Cells of the oligodendrocyte lineage that are O4 positive and CNP positive
are post mitotic and terminally differentiated cells that begin to express myelin
markers such as myelin basic protein (MBP), proteolipid protein (PLP), myelin
associated glycoprotein (MAG), myelin-oligodendrocyte glycoprotein (MOG), and
the galactocerebrosides (GalC) that are recognized by the O1 antibody (Figure
1.2). At this stage, the beginnings of membranous sheets develop in culture and
these cells are classified as mature oligodendrocytes (Bansal et al., 1989). The
myelinating oligodendrocyte will remodel its process network and extensively
produce myelin membranes to wrap axonal segments (Helmut Kettenmann,
2005, Bauer et al., 2009).
MBP is one of the major myelin protein components in the CNS (Baumann
and Pham-Dinh, 2001, Helmut Kettenmann, 2005). One of MBP’s functions is the
compaction and binding of opposing cytoplasmic myelin membranes (Readhead
et al., 1990). MBP’s role in compaction is made evident in the shiverer mutant
mouse line. In this mouse line, the Mbp gene is mostly deleted and the protein is
absent resulting in hypomyelination and the formation of uncompacted myelin in
the CNS (Readhead and Hood, 1990, Readhead et al., 1990, Shine et al., 1990).
MBP is expressed in multiple isoforms in the rodent and other mammalian
systems. In the mouse, MBP contains 7 exons which through alternative splicing
of exons 2, 5 and 6 account for the four major “classic “ MBP variants
(Campagnoni, 1988, Campagnoni and Macklin, 1988, Baumann and Pham-Dinh,
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2001, Helmut Kettenmann, 2005). The molecular weight of each one of the 4
classic MBP’s are: 21.5kDa, 18.5kDa, 17kDa, and 14kDa (Helmut Kettenmann,
2005). The splicing of these different transcripts is developmentally regulated.
This can be seen in the larger 17 and 21.5kDa isoforms that contain exon2.
Exon2 containing MBP is seen early on during oligodendrocyte differentiation,
and interestingly, it is also seen in chronic MS samples where presumed limited
and insufficient remyelination is occurring (Capello et al., 1997, Nagasato et al.,
1997). The non-exon 2 containing isoforms are considered specific for the
myelinating stages of the lineage (Campagnoni, 1988, Campagnoni and Skoff,
2001).
Proteolipid protein (PLP) is another major myelin protein component in the
CNS. This highly conserved protein is a cell-surface protein that spans the
membrane four times, forming two extracellular loops, which are thought to
mediate adhesion between the outer (extra cellular side) membranes of the
myelin sheath (Popot et al., 1991, Baumann and Pham-Dinh, 2001). PLP has a
splice variant with the name DM20 (Campagnoni, 1988, Timsit et al., 1995, Nave
and Trapp, 2008). Plp1/Dm20 is a 7 exon encoded gene, where use of an
internal splice donor site within exon 3 results in a 35 amino acid deletion
generating the splice variant DM20 (Helmut Kettenmann, 2005). The expression
of each one of these splice variants is developmentally regulated, where DM20 is
the earlier expressed isoform and PLP is expressed later as the oligodendrocyte
matures (Timsit et al., 1995).

16

Functionally, the significance of PLP has been demonstrated by mouse
mutant and knockout studies. The PLP mutant mouse jimpy, which has a mutant
form of the protein, has a reduced number of oligodendrocytes and thin myelin
resulting in premature death (Knapp et al., 1986, Duncan et al., 1989). However,
in Plp1 knockout mice, there is no oligodendrocyte loss or loss of myelin. Axonal
swellings and axonal degeneration were noticed in these animals; therefore, the
phenotypic response seen in the jimpy mice has been suggested to be a result of
protein misfolding in the mutant PLP (Griffiths et al., 1998).

The oligodendrocyte cytoskeleton
From specification to myelination, oligodendrocytes not only progress
through changes in gene expression but they also undergo extensive changes in
morphology. Oligodendrocyte morphological development can be broken down
into three steps. The first step is cell spreading and formation/extension of a
complex process network. The second step is the establishment of axonal
contact and the extension/spreading of the myelin sheath. Compaction and
maintenance of the myelin sheath is the final stage (Bauer et al., 2009). All of
the three steps mentioned above require large-scale morphological changes in
the oligodendrocyte that will eventually make the myelin sheath. These largescale changes are mediated to a large extent by changes in the cellular
cytoskeleton (Bauer et al., 2009).
The oligodendrocyte cytoskeleton is composed of microtubules and
microfilaments. These cytoskeletal components and many of their regulatory

17

elements are also found in other types of cells. This is in contrast to intermediate
filaments, which are present in the non-oligodendroglia CNS cell types
(astrocytes and neurons) but absent in cells of the oligodendrocyte lineage
(Bauer et al., 2009). Microfilaments and microtubules are both part of the
cytoskeleton but their roles differ somewhat when it comes to function. Process
outgrowth is primarily mediated by microfilaments because of their location and
their ability to directly connect via actin binding proteins to the plasma membrane
(Bauer et al., 2009). Microtubules, on the other hand, are primarily thought to
mediate process stability and localize to the cellular process once the
microfilament network has moved the process forward (Bacon et al., 2007, Chan
et al., 2009, Pollard and Cooper, 2009). Furthermore, both microtubules and
microfilaments are polarized polymers and both can be associated with motor
proteins such as kinesins, dyneins, and myosins for the transport of cellular
organelles, vesicles, proteins, and mRNAs (Ross et al., 2008). The polarity of
these cytoskeletal proteins is based on the direction and site of addition of
subunits to the growing polymer. The fast growing end (or plus end) of these
polymers is termed thusly because it is the site of addition of individual subunits
while the opposite end (the minus end) is unstable and usually the site of
depolymerization (Bauer et al., 2009, Pollard and Cooper, 2009).
Microtubules are comprised of alpha and beta-tubulin heterodimers.
These heterodimers form a classic hollow cylindrical tube. In the cellular
processes of oligodendrocytes, microtubules are arranged parallel to the
orientation of the process (Lunn et al., 1997, Song et al., 2001, Bauer et al.,
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2009). In the cell body of the oligodendrocyte, however, the microtubule network
is arranged in a mesh-like pattern (Lunn et al., 1997). It has been shown that
oligodendrocytes express a unique form of beta tubulin (βIV-tubulin) that is
apparently not expressed by any other CNS-derived cell (Terada et al., 2005).
The function of this unique form of tubulin is still under investigation. Microtubules
can go through post-translational modifications including acetylation. Acetylated
α-tubulin seems to be associated with stable processes in more mature
oligodendrocytes since it appears to be present in primary processes but not at
the most distal tips of the process (Lunn et al., 1997, Song et al., 2001).
The other cytoskeletal component that oligodendrocytes possess is actin.
Actin is found in oligodendrocytes in two distinct forms: globular monomer (Gactin) and filamentous (F-actin) (Song et al., 2001, Le Clainche and Carlier,
2008, Pollard and Cooper, 2009). F-actin is formed by the polymerization of Gactin subunits. Spontaneous nucleation of G-actin is not likely because of the
stability of actin and the high threshold of nucleation that actin possesses (Bauer
et al., 2009, Pollard and Cooper, 2009). Actin utilizes specific actin binding and
regulatory proteins that act as catalysts for actin nucleation. Two examples for
such proteins are the actin related protein 2/3 (Arp2/3) complex and the formin
family of proteins (Bacon et al., 2007, Bauer et al., 2009, Chan et al., 2009,
Pollard and Cooper, 2009).

Oligodendrocyte differentiation – changes in actin cytoskeletal
organization
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For the purposes of this dissertation, understanding the cytoskeletal
changes that occur during oligodendrocyte differentiation is critical for a better
understanding of the signaling pathways that regulate oligodendrocyte
differentiation and that could be targeted to stimulate endogenous repair of the
myelin sheath in MS. Process extension is the initial step in oligodendrocytes
developing a complex process network and subsequently the myelin sheath.
Once terminal differentiation has occurred, a complex process network is
established by rearranging and reorganizing the cellular cytoskeleton (Bauer et
al., 2009). This process requires well coordinated polymerization and depolymerization that regulates the changes that are occurring (Bradke and Dotti,
1999, Mallavarapu and Mitchison, 1999, Pollard and Cooper, 2009, Koskinen et
al., 2012). The term named for this addition of subunits (polymerization) to the
positive end of the microfilament and the removal of subunits (depolymerization)
from the minus end of the subunit is called treadmilling. In general, process
outgrowth and membrane sheet formation are mediated by filopodia and
lamellipodia production; the generation of which is caused by stimulation of actin
polymerization as well as actin filament branching and bundling (Song et al.,
2001, Bacon et al., 2007, Pollard and Cooper, 2009). Filopodia are formed in the
presence of parallel F-actin finger-like bundles that are the driving force of
process extension. Lamellipodia are the lagging structures that fall into formation
after filopodia have somewhat extended. It is generally understood that filopodia
are formed first and then due to branching, the lamellipodia push out the leading
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edge of the oligodendrocyte process (Song et al., 2001, Bacon et al., 2007,
Pollard and Cooper, 2009).
The actin dynamics that control filopodia and lamellipodia formation and
movement are regulated by actin binding proteins such as the Arp 2/3 complex
and neural-Wiskott Aldrich Syndrome Protein (N-WASP) (Bacon et al., 2007,
Delatour et al., 2008). Arp2/3 is a complex that binds to the sides of existing
("mother") filaments and initiates growth of a new ("daughter") filament at a
distinctive angle from the mother filament and initiates branching of F-actin
filaments (Pollard, 2007, Delatour et al., 2008). N-WASP has been shown to aid
in actin filament branching by interacting with Arp2/3 (Bacon et al., 2007).
Importantly, N-WASP has been shown to be required for lamellipodia formation
in maturing oligodendrocytes (Bacon et al., 2007). Rho GTPases signal to many
of the actin-associated proteins and promote actin polymerization or
depolymerization. Rho GTPases are major regulators of the actin cytoskeleton
and mediate process elongation and branching as well as inhibition of process
formation (Bauer et al., 2009). The three most common and best studied
members of the Rho GTPase family are CDC42, Rac1, and RhoA. Process
retraction is often found mediated by the activation of RhoA. RhoA in turn
activates ROCK, which signals to the actin cytoskeleton to initiate process
retraction (Wolf et al., 2001). In contrast to RhoA, activation of CDC42 and Rac1
results in process outgrowth by stimulating actin polymerization and branching
(Colognato et al., 2002, Bacon et al., 2007, Sloane and Vartanian, 2007).
Interestingly, knockout of CDC42 or Rac1 in mice does not result in deficient
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myelin formation. This could be due to the redundancy of the two actin
polymerizing proteins that can compensate for each other (Thurnherr et al.,
2006).
In addition to actin polymerization, the depolymerization or (breaking
down) of the actin cytoskeleton by certain factors is equally important in the
formation and extension of new and current oligodendrocyte processes. It is
critical that the periods of actin destabilization be followed up with periods of actin
stabilization to achieve a proper balance of actin dynamics (Ballestrem et al.,
1998, Bradke and Dotti, 1999). Oligodendrocytes express the actin
depolymerizing factor cofilin, which appears to be localized to the
oligodendrocyte “growth cone” (Fox et al., 2006a). Other than localization, much
of the function of cofilin has not been specifically described in oligodendrocytes
as it has been in other cell types. However, based on the localization and
conservation of the protein, it is assumed that cofilin functions as an actin
depolymerizer similar to its role in Schwann cells and other cell types (Sparrow et
al., 2012). This depolymerization of the actin cytoskeleton by cofilin allows the
redistribution of actin filaments by breaking down longer filaments into shorter
filaments and monomeric subunits (Lappalainen and Drubin, 1997, Sparrow et
al., 2012).
In addition to actin binding proteins and Rho GTPases, there are several
other proteins that are linked to process extension in more mature
oligodendrocytes. Fyn, a member of the Src family kinases (SFK), promotes
process extension and morphological differentiation by inactivating RhoA (Wolf et
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al., 2001, Liang et al., 2004). This inactivation of RhoA is developmentally
regulated and upon inactivation by Fyn, there is an increase in process extension
(Wolf et al., 2001, Liang et al., 2004). Dominant negative constructs in vitro or
knockout and mutants in vivo have shown that Fyn is necessary for proper
myelination of the CNS. When Fyn is downregulated in vitro or knocked out in
vivo, process outgrowth is inhibited and a hypomyelination phenotype is
observed respectively (Wolf et al., 2001, Klein et al., 2002, Liang et al., 2004).
Fyn has many downstream effects on process extension. One of these
down stream effects is the inhibition of Myosin II, which seems to increase
process extension in oligodendrocytes. Actin-associated motor protein nonmuscle myosin II (NMII) is regulated by phosphorylation of a specific regulatory
chain and is a key regulator of actinomyosin assembly. More specifically, activity
of NMII in oligodendrocytes is controlled by Fyn kinase via downregulation of
RhoA-ROCK-NMII phosphorylation (NMII inhibition) (Conti and Adelstein, 2008,
Wang et al., 2008, Wang et al., 2012). When myosin II is inhibited in culture,
there is an increase in actin polymerization, branching, and the amount of
myelinated segments formed in a co-culture system (Conti and Adelstein, 2008,
Wang et al., 2012).
Kelch-related acting binding protein Mayven is also linked to process
extension in differentiating oligodendrocytes (Jiang et al., 2005). Mayven is
expressed and upregulated during oligodendrocyte differentiation where
oligodendrocytes form a more complex process network. Mayven promotes
process extension by binding actin to facilitate cytoskeletal rearrangement (Jiang
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et al., 2005). Mayven protein binding domains suggest that Fyn and Mayven may
interact and play a role in the dynamics of cytoskeletal rearrangement leading to
process extension (Jiang et al., 2005).
Major myelin proteins have also been shown to affect the actin
cytoskeleton and process extension. For example, MBP has been shown to act
as a scaffolding protein that links the lipid bilayer to bind actin, induces F-actin
polymerization, and bundles actin in a phosphorylation dependent manner
(Boggs, 2006, Boggs et al., 2006, Boggs et al., 2012). MBP is not
phosphorylated when located within the sheets of myelin; therefore it can not
perform as a scaffolding protein (Boggs, 2006, Boggs et al., 2006, Boggs et al.,
2012). When MBP is phosphorylated, it is localized in the cell body. This
phosphorylated state of MBP prevents interaction with actin in the
oligodendrocyte cell body (Boggs, 2006, Boggs et al., 2006, Boggs et al., 2012).
CNP is another myelin protein that affects the cytoskeleton of
oligodendrocytes. Studies show that when CNP is upregulated before and during
myelination, it can bind to both microtubules and microfilaments. More
specifically, CNP acts in the processes of cells and aids the connections of the
actin cytoskeleton to the membrane. Studies have suggested that CNP is
important in filopodia formation in oligodendrocytes (De Angelis and Braun,
1996a, b).
All of the actions described above are internally derived in the cell.
However, extracellular matrix (ECM) components and signaling molecules signal
to internal proteins governing process formation and extension. The ECM
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components laminin, fibronectin, and collagen all interact with membrane
proteins such as integrins. These integrins are heterodimers made of an α and a
β-chain. Oligodendrocytes express αvβ1, αvβ3, αvβ5, α6β1, and αvβ8
(Colognato et al., 2002, Benninger et al., 2006, Colognato and Tzvetanova,
2011). Most of these integrins (especially the αv integrins) seem to be
developmentally regulated and expressed at different stages of oligodendrocyte
development (Colognato and Tzvetanova, 2011). It should be noted that α6β1
integrin seems to play a key role in the axo-glial interaction that controls CNS
myelin wrapping (Lee et al., 2006).
Simply put, oligodendrocyte process extension is assisted by a
conglomeration of different actin binding proteins and signaling molecules that
mainly function in two roles by either allowing actin to polymerize or to
depolymerize and rearrange the actin cytoskeleton. Both of these functions can
happen simultaneously and when combined, allow for constant fluidity in the
actin cytoskeleton and proper process elongation. There has been a good
amount of research based on the characterization of the molecular players that
govern polymerization and depolymerization. However, little is known about the
molecular players that regulate stabilization of the actin cytoskeleton. The data
highlighted in this dissertation demonstrates the importance of the actin
binding/stabilizing protein Calcium/calmodulin-dependent protein kinase II beta
(CaMKIIβ) described below.

Calcium/calmodulin-dependent protein kinase II (CaMKII)
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Calcium/calmodulin-dependent protein kinase II (CaMKII) has been mainly
described as a fine-tuned calcium sensor and fundamental kinase for neuronal
activity in the development of memory and synaptic plasticity in the CNS
(Hudmon and Schulman, 2002b, a, Griffith, 2004). Much of the research on
CaMKII’s role in neurons has focused on understanding the mechanism of
synaptic plasticity and increases in long-term potentiation (LTP), which is critical
in learning and memory (Hudmon and Schulman, 2002b, a, Griffith, 2004).
Research highlighting CaMKII’s relationship with oligodendrocytes is rare.
Currently, there are only a couple of research articles in the literature. In one of
the articles, CaMKII’s expression in oligodendrocytes was only mentioned as part
of their supplemental microarray data (Dugas et al., 2006). Another mention of
CaMKII being involved in oligodendrocytes comes from a publication in which the
myelin proteome was characterized (Jahn et al., 2009). Since CaMKII has hardly
been described in oligodendrocytes, little is known about CaMKII’s role and
function in these cells. The lack of research into the function and expression of
CaMKII in oligodendrocytes is likely not due to its lack of importance compared to
neurons; rather, it is probably due to the overwhelming amount of researchers
characterizing synaptic plasticity and learning and memory in neurons.
Additionally, expression levels of CaMKII are much higher in neurons and may
have been overlooked in oligodendrocytes. Given the similarities in certain
aspects of morphological maturation between oligodendrocytes and neurons, it is
plausible to apply some of the findings in CaMKII neuronal research to
oligodendrocyte development (Fox et al., 2006a).
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Calcium/calmodulin-dependent protein kinase II (CaMKII) is a serine/
threonine kinase (Hudmon and Schulman, 2002b, a, Griffith, 2004) that
phosphorylates substrates at a serine or threonine site (Hudmon and Schulman,
2002b, a, Griffith, 2004). CaMKII encodes four different genes in the mammalian
system (Hudmon and Schulman, 2002b, a, Griffith, 2004) and seven different
genes in teleosts (Rothschild et al., 2007, Rothschild et al., 2009). In the
mammalian system, these genes are given the names Camk2a, Camk2b,
Camk2g, and Camk2d. Multiple splice variants exist with each of these genes
(Hudmon and Schulman, 2002b, a, Griffith, 2004).

Basic structure and organization of CaMKII
CaMKII contains several functional domains within its protein structure.
The catalytic domain which is located at the N-terminal end of the protein is
where ATP and substrate binding sites are located (Hudmon and Schulman,
2002b, a, Griffith, 2004) (Figure 1.4). The regulatory region is upstream of the
catalytic domain and consists of two domains (Figure 1.4). The two domains in
this regulatory region are an autoinhibitory domain and a Ca2+/ CaM binding
domain (Hudmon and Schulman, 2002b, a, Griffith, 2004) (Figure 1.4). These
two domains regulate the activation of CaMKII. (Hudmon and Schulman, 2002b,
a). The association domain is located C-terminal to the Ca2+/ CaM binding
domain (Hudmon and Schulman, 2002b, a) (Figure 1.4). In between the
association domain and the regulatory domain is a variable domain or “linker
domain” (Griffith, 2004, Kristensen et al., 2011). This domain contains isozyme-
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specific regions and multiple splice variants (Hudmon and Schulman, 2002b, a,
Griffith, 2004). The association domain allows CaMKII monomers to join
together, forming a large functional 12-subunit holoenzyme (Schulman and
Greengard, 1978a, b, Hudmon and Schulman, 2002b, a, Griffith, 2004) (Figure
1.5). They can form homo and hetero-oligomers containing more than one
Camk2 gene. Hetero-oligomerization provides inter-subunit phosphorylation
when CaMKII is being activated (Griffith, 2004, Lantsman and Tombes, 2005).

Activation of CaMKII’s catalytic activity
After the binding of calcium (Ca2+) to calmodulin (CaM), Ca2+/ CaM binds
with high affinity to the Ca2+/CaM binding site within the regulatory domain of
CaMKII (Hudmon and Schulman, 2002b, a, Griffith, 2004) (Figure 1.5). After the
binding of Ca2+/ CaM to its appropriate binding site, autophosphorylation occurs.
The autoinhibitory domain releases the catalytic domain, allowing access to
phosphorylation sites critical for inter-subunit phosphorylation of the Thr286 site
(for CaMKIIα) (Hudmon and Schulman, 2002b, a, Griffith, 2004) (Figure 1.5).
Once the subunits are phosphorylated, the kinase remains at 100 percent of its
activity even after intracellular calcium levels fall (Hudmon and Schulman, 2002b,
a, Griffith, 2004) (Figure 1.5). Ca2+/ CaM is tightly bound to the binding site,
creating a state of activity known as “active-CaM trapped” (Hudmon and
Schulman, 2002b, a, Griffith, 2004) (Figure 1.5). Over time, Ca2+/ CaM
dissociates from the kinase and CaMKII will remain active at a lower state. This
state is known as the active-Ca2+ independent state (Hudmon and Schulman,
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2002b, a, Griffith, 2004) (Figure 1.5). After Ca2+/ CaM dissociates from CaMKII,
two other threonine sites are exposed and can be autophosphorylated. Once
these two other threonine (Thr306 and Thr307) sites (for CaMKIIα) have been
phosphorylated, the phosphates block the Ca2+/ CaM binding site and do not
allow further association with Ca2+/ CaM (Hudmon and Schulman, 2002b, a,
Griffith, 2004) (Figure 1.5). This state, called “active capped,” possesses only 20
to 80 percent of CaMKII’s full capacity of activity (Hudmon and Schulman, 2002b,
a, Griffith, 2004) (Figure 1.5). Over time, phosphatases act and return the
partially active CaMKII to its inactive state (Griffith, 2004) (Figure 1.5).

CaMKII as an actin binding and actin cytoskeleton regulatory protein
It has been recently shown that CaMKII can play a role in the regulation of
the actin cytoskeleton (Shen et al., 1998, Fink et al., 2003, O'Leary et al., 2006,
Okamoto et al., 2007, Lin and Redmond, 2008, 2009, Sanabria et al., 2009).
The CaMKII isoform that has been best described for the binding to F-actin is the
β isozyme (Shen et al., 1998). Further supporting the relationship between actin
and CaMKII, studies using RNA interference targeted to CaMKIIβ resulted in a
significant reduction of actin synaptic volume (Okamoto et al., 2007, Lin and
Redmond, 2008, 2009, Okamoto et al., 2009). It has been shown that
oligomerization of CaMKIIβ is needed for actin binding but catalytic activity is not
essential for actin binding (Okamoto et al., 2007, Lin and Redmond, 2008). An
actin binding domain that is N-terminal within the variable domain of CaMKIIβ is
responsible for F-actin binding (O'Leary et al., 2006, Okamoto et al., 2007).
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The structure and the composition of the variable domain play a key role
in the protein’s regulation and binding abilities to actin. Expression of Camk2b in
the adult brain is prevalent with the splice variants of exons 1,2,3,4 and 5 in the
variable region. These results further support the evidence that strict control over
an important actin binding element is regulated with fine precision. Exon 1 in the
variable domain seems to be the actin binding region that is unique to Camk2b
(O'Leary et al., 2006). The first, third, and/or fourth exon in the variable region
seem to control the targeting to the F-actin cytoskeleton. Deletion of exon 1 in
the variable region inhibits actin bundling and colocalization with bundled actin,
demonstrating that the first exon in the variable region is critical for binding and
bundling of actin (O'Leary et al., 2006).
The function of CaMKIIβ is more complex than only its use as a
multifunctional kinase. CaMKIIβ is responsible for the reorganization and
stabilization of the actin cytoskeleton (Sanabria et al., 2009). While CaMKIIβ
seems to possess a unique actin binding site, other CaMKII isoforms have been
recently reported to also bind to actin via a location C-terminal to the variable
domain (Hoffman et al., 2013).
CaMKIIβ has been shown to play an important role in the regulation of
actin dynamics within the dendritic spine (Okamoto et al., 2007, Okamoto et al.,
2009, Sanabria et al., 2009). The model that has been proposed by Okamoto et
al. (2009) uses CaMKIIβ as a “gating” mechanism that will maintain spine
structure at Ca2+ resting levels. When Ca2+ levels increase, modification of the
actin cytoskeleton is observed. CAMKIIβ then preserves the new modification for
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periods of time (Okamoto et al., 2009). This proposed model starts off with
CaMKIIβ bundling actin in a resting basal state in the dendritic spine. Once Ca2+
enters the cell and activates CaMKIIβ, it disassociates from actin and allows for
F-actin unbundling. Actin polymerization, F-actin rearrangement, and spine
enlargement soon follow after dissociation of CaMKIIβ from f-actin bundles.
Lastly, CaMKIIβ will once again accumulate in the dendritic spine and bundle
the newly rearranged f-actin bundles, allowing for cytoskeletal stabilization
(Okamoto et al., 2009).
The model of CaMKIIβ described by Okamoto et al. (2009) is supported by
many experiments that show the relevance of CaMKIIβ location and its
association with the actin cytoskeleton. By overexpressing Camk2b, researchers
have observed an accumulation of the protein in spines. When CaMKII is
inhibited (CaMKII inhibitor KN-93), researchers also observed alternations and
spine remodeling. The overexpressed accumulation of CaMKIIβ in these
dendritic spines demonstrates the fact that the protein is bundling actin and
stabilizing the spine structure in an activity-dependent manner (Shi and Ethell,
2006, Okamoto et al., 2007, Okamoto et al., 2009).
The actin network is responsible for the outgrowth of dendrites. When
CaMKIIβ is knocked down, it impairs outgrowth of these dendrites (Fink et al.,
2003). In addition to binding and bundling F-actin, CaMKIIβ binds to monomeric
actin (G-actin) and inhibits actin polymerization that is diminished by the binding
of Ca2+/ CaM (Sanabria et al., 2009). This binding of G-actin enhances the
structural rigidity of F-actin (Sanabria et al., 2009). Furthermore, CaMKIIβ has
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been shown to control the rate and extension of actin polymerization through
binding and sequestration of G-actin (Sanabria et al., 2009, Hoffman et al.,
2013).
CaMKIIβ activation by autophosphorylation can facilitate actin unbinding
(O'Leary et al., 2006, Okamoto et al., 2007, Okamoto et al., 2009, Sanabria et al.,
2009). When using different mutant constructs, strong correlations with
colocalization are seen in the A303R (calmodulin binding mutant) mutant and the
K43R (autophosphorylation mutant) mutant. This demonstrates that CaMKIIβ
binds to actin in a catalytic independent/dependent manner. Once the
phosphorylation of the main autophosphorylation site is activated, CaMKIIβ
appears unbound to actin. This result is shown when using the T287D
(constitutively active mutant) mutant that did not show colocalization with actin in
Cos-7 cells when transfected (O'Leary et al., 2006). CaMKIIβ binding to F-actin
did not increase phosphorylation of a substrate peptide, indicating that the
activation state of the kinase was not changed (Fink et al., 2003).
Although the CaMKIIβ information presented in this section is based on
neuronal research, the findings can be applied to oligodendrocytes due to the
commonalities in the actin cytoskeleton. In oligodendrocytes as well as neurons,
the actin cytoskeleton plays a critical role in the formation, extension, and
remodeling of processes that extend from the cell body. CaMKII’s involvement in
oligodendrocyte development is potentially imperative, as oligodendrocytes are
dependent on creating these complex processes and maintaining a regulation of
the cytoskeleton similar to the model proposed in neurons.
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Figure 1.1: Oligodendrocyte origination points and migratory patterns in brain
and spinal cord. A: Red represents the first wave of development and migration
in the rodent ventral spinal cord. Green represents the origination and migration
of the second wave of development in more dorsally located positions of the
spinal cord. B: Rodent brain displaying sagittal section (upper) showing the site
of origination for oligodendrocytes and (orange) their rostral caudal radial
migration to populate the cortex (green arrows). The rostral migratory stream is
the specialized rout that allows cells to migrate to the olfactory bulb from the SVZ
(red). Coronal sections of the rodent brain (lower) showing oligodendrocyte
origination from the SVZ (orange) and their dorsolateral radial migration pattern
from the SVZ into the cortex (green arrows). Adapted from (Cayre et al., 2009;
Richardson et al., 2006).
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Rodent Brain

Figure 1.2: Oligodendrocyte lineage and some specific markers that are
expressed at different developmental stages. Adapted from (Baracskay et al.,
2007; de Castro and Bribian, 2005; Fox et al., 2004; Pfeiffer, et al.,1993).
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Figure 1.3: Signaling network of oligodendrocyte development. Green arrows
indicate stimulation. Red bars indicate repression or inhibition. Blue arrows
represent developmental time between stages of oligodendrocyte development.
Adapted from (Nicolay et al., 2007).
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Figure 1.4: The structure and functional domains of CaMKII. Phosphorylation
sites are representative for CaMKIIα. The phosphorylation sites depicted are
conserved between CaMKII isozymes (Lisman et al., 2002).
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Figure 1.5: Activation of CaMKII. A six subunit holoenzyme rather than a 12
subunit holoenzyme is shown for simplicity. Phosphorylation sites are
representative for CaMKIIα (Griffith, 2004b).
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CHAPTER 2
CaMKIIβ Regulates Oligodendrocyte Maturation and CNS Myelination
(This chapter was accepted as a paper in the Journal of Neuroscience in May of
2013. The work reported for this manuscript is based primarily on my own efforts.
Assistance was provided by Dr. Jeffrey Dupree (electron microscope imaging
Figure 2.4)

Introduction
During development, oligodendrocytes, the myelinating cells of the central
nervous system (CNS), undergo a lineage progression during which bipolar
progenitors give rise to cells with an extended process network that then
transition into mature oligodendrocytes generating the myelin sheath (Pfeiffer et
al., 1993, Baumann and Pham-Dinh, 2001). The morphological aspects of this
progression are to a large extent regulated by changes in the cellular
cytoskeleton (Bauer et al., 2009). However, the exact mechanisms by which the
cellular cytoskeleton regulates oligodendrocyte maturation and CNS myelination
are currently only poorly understood.
One of the molecular players that emerges as an important regulator of the
actin cytoskeleton is calcium/calmodulin-dependent kinase type IIβ (CaMKIIβ).
CaMKIIβ belongs to a family of highly conserved serine/threonine kinases, which
in mammals is encoded by four different genes (Camk2a, Camk2b, Camk2g,
Camk2d) giving rise to four isozymes (CaMKIIα, CaMKIIβ, CaMKIIγ, CaMKIIδ)
(Tombes et al., 2003). Structure-functionally, CaMKII monomers are composed
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of four domains, a kinase catalytic, an autoinhibitory (regulatory), an association
(oligomerization) and a central variable domain that is subject to alternative
splicing and located distal to the autoinhibitory domain (Hudmon and Schulman,
2002b). Interestingly, CaMKIIβ has been characterized to also possess a
distinctive actin binding domain (Okamoto et al., 2009), which has been
implicated in mediating actin filament stabilization/bundling (Shen et al., 1998,
Fink et al., 2003, O'Leary et al., 2006, Okamoto et al., 2007, Lin and Redmond,
2008). While primarily characterized in neurons, CaMKII genes including
CaMKIIβ appear to also be expressed by cells of the oligodendrocyte lineage
(Cahoy et al., 2008). Thus, we examined here the role of CaMKII and in
particular CaMKIIβ in regulating oligodendrocyte maturation and myelination.

Materials and Methods
Animals. Sprague-Dawley female rats with early postnatal litters were obtained
from Harlan Laboratories, Inc. (Indianapolis, IN). Camk2b-/- and Camk2bA303R
mice (both in the F2 129P2-C57BL/6 background; van Woerden et al., 2009;
Borgesius et al., 2011) were generated and bred at Erasmus University Medical
Center. Animal studies were approved by the Institutional Animal Care and Use
Committee at Virginia Commonwealth University or a Dutch Ethical Committee
for animal experiments.
Primary oligodendrocyte cultures. Primary oligodendrocytes were isolated
from P3 rat brains by A2B5 immunopanning (Barres et al., 1992) and then
cultured in differentiation medium for at least 48 hours (Lafrenaye and Fuss,
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2011). Under these conditions, the majority of cells represented post-migratory,
premyelinating oligodendrocytes as they expressed the O4 antigen (Sommer and
Schachner, 1982, Warrington et al., 1993) (data not shown).
For CaMKII inhibition experiments, cells were cultured for 44 to 48 hours
followed by incubation with 1) KN-93 or its inactive analog KN-92 (EMD Millipore,
Billerica, MA), 2) myristoylated autocamtide-2 related inhibitory (Myr-AIP) or
myristoylated control (scrambled AIP sequence) peptide (Enzo Life Sciences,
Inc., Farmingdale, NY) or 3) KN93 or KN92 in combination with jasplakinolide
(Enzo Life Sciences, Inc., Farmingdale, NY).
For siRNA-mediated gene silencing, cells were cultured for 20 to 24 hours
and then transfected with siGLO Green transfection indicator along with either an
siRNA SMARTpool directed against rat Camk2a, b, g or d or a control nontargeting siRNA SMARTpool (all from Thermo Fisher Scientific, Inc., Waltham,
MA) (Lafrenaye and Fuss, 2010).
Oligodendrocyte morphology analysis. Oligodendrocyte morphology was
assessed by determining the process index (total area found to be O4-positive
minus the area occupied by the cell body) as previously described (Dennis et al.,
2008). For the generation of representative images, confocal laser scanning
microscopy was used (Zeiss LSM 510 META NLO; Carl Zeiss Microscopy, LLC,
Thornwood, NY). Images represent 2D maximum projections of stacks of 0.4 µm
optical sections.
CaMKIIβ-F-actin co-localization analysis. Cells of the oligodendroglia cell line
CIMO (Bronstein et al., 1998) were nucelofected (Lonza Cologne GmbH,
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Cologne, Germany) with a plasmid encoding GFP-CaMKIIβ (Okamoto et al.,
2004), and F-actin was visualized using Acti-stain 555 phalloidin (Cytoskeleton,
Inc., Denver, CO).
PCR and Western blot analysis. For the determination of alternative splicing
profiles, endpoint PCR analysis was performed using the following gene-specific
primer pairs:
Camk2a: Forward: 5’-TGGCCACCAGGAACTTCTCCGGAGG-3’ and Reverse:
5’-TGCGGCAGGACGACGGAGGGCGCCCCAGA-3’)
Camk2b: Forward: 5’-CACGGAATTTCTCAGTGGGCAGACAG-3’ and Reverse:
5’-CGCAGCTCTCACTGCAGCGGGGCCAC-3’
Camk2g:

Forward: 5’-CGCTCCGGAAAGGGTGCCATCCTCACAACCATGC-3’

and Reverse: 5’-TCCGGAGCGTCTCCTCTGACTGACTGGTGCGAGG-3’
Camk2d:

Forward:

5’-CGCTCCGGAACGAGAAATTTTTCAGCAGCCAAGA-3’

and Reverse: 5’-TCCGGATCCTGGCTTGATGGGGACTGTTGGGGAC-3’.
For the determination of relative mRNA expression levels, quantitative (q)RTPCR was performed on a CFX96 Real-Time PCR Detection System (BioRad,
Hercules, CA) using the following gene-specific primer pairs:
Camk2a: Forward: 5′-ACGGAAGAGTACCAGCTCTTCGAGG-3′ and Reverse: 5′CCTGGCCAGCCAGCACCTTCAC-3′
Camk2b: Forward: 5′-GTCGTCCACAGAGACCTCAAG-3′ and Reverse: 5′CCAGATATCCACTGGTTTGC-3′
Camk2g: Forward: 5′-ACGCAAGTTCAACGCCCGGAGAA-3′ and Reverse: 5′AGGCTCTTGGCAGCTTGCCCG-3′
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Camk2d: Forward: 5′-TGCCGTCTCTGAAGCACCCCA -3′ and Reverse: 5′ACCAAGTAATGGAAGCCCTCTTCGG-3′
Mbp

(exon

2

containing

isoforms):

ACTTGGCCACAGCAAGTACCATGGACC-3′

and

Forward:

5′-

Reverse:

5′-

TTGTACATGTGGCACAGCCCGGGAC-3′
Mpb (all isoforms): Forward: 5′-GTGACACCTCGTACACCCCCTCCAT-3′ and
Reverse: 5′-GCTAAATCTGCTGAGGGACAGGCCT-3′
Plp: Forward: 5’-CCACACTAGTTTCCCTGCTCACCT-3’ and Reverse: 5’GGTGCCTCGGCCCATGAGTT-3’
Cyclophilin (as reference gene): Forward: 5′-GGAGACGAACCTGTAGGACG-3′
and Reverse: 5′-GATGCTCTTTCCTCCTGTGC-3’
For comparing the expression levels of the different Camk2 genes, R0 values
were determined as described by Peirson et al. (2003)(Peirson et al., 2003). To
determine relative expression levels, the ΔΔCT method was used (Livak and
Schmittgen, 2001).
For Western blot analysis, anti-CaMKIIβ (Life Technologies, Grand Island,
NY) and anti-GAPDH antibodies (Millipore, Billerica, MA) were used. Bound
antibodies were detected using enhanced chemiluminescence (ECL) in
combination with VersaDoc imaging (BioRad Laboratories, Hercules, CA).
Electron Microscopic Analysis. Spinal cord tissue was prepared and analyzed
by electron microscopy as previously described (Dupree et al., 1998, Marcus et
al., 2006, Forrest et al., 2009). Numbers of axons were determined manually per

47

field of view (14.6 µm2). G-ratios were determined as previously described
(Dupree et al., 1998, Marcus et al., 2006, Forrest et al., 2009).

Results
Camk2b is the predominant Camk2 gene expressed by differentiating
oligodendrocytes
To determine the extent and alternative splicing pattern of Camk2 gene
expression in differentiating oligodendrocytes, RT-PCR analysis was performed
using gene-specific primer pairs spanning the variable domain (Fig. 2.1A;
(Hudmon and Schulman, 2002b, Tombes et al., 2003). Sequence analysis of the
resulting amplification products revealed the expression of Camk2a, b and d but
not g. All of the three oligodendrocyte-derived genes were found to give rise to
multiple alternatively spliced isoforms in a gene-specific fashion. Interestingly, the
majority of Camk2b isoforms contained the alternatively spliced exon I of the
variable domain, which has been implicated in conferring actin binding/stabilizing
properties to CaMKIIβ (O'Leary et al., 2006).
To

determine

the

quantitative

contribution

of

each

of

the

three

oligodendrocyte-derived Camk2 genes to overall Camk2 expression, qRT-PCR
was performed using primer pairs located outside of the variable region and not
affected by alternative splicing. This analysis revealed a quantitative expression
of Camk2b > Camk2d > Camk2a (Fig. 2.1B).

Inhibition of CaMKII activity restrains the morphological maturation of

48

differentiating oligodendrocytes
The above expression analysis suggested that CaMKII and in particular CaMKIIβ
may play an important functional role in differentiating oligodendrocytes. To
assess such a potential role of CaMKII, differentiating oligodendrocytes were
treated with KN-93, a membrane permeable pharmacological inhibitor of CaMKII
activity, or its inactive derivative KN-92, and process morphology, as a measure
for oligodendrocyte maturation, was determined (Dennis et al., 2008). Treatment
with KN-93 caused a decreased process index (Fig. 2.2A,B) at 10 but not 1 µM.
Such concentration-dependency is in agreement with a half-maximal inhibition of
CaMKII at a KN-93 concentration of approximately 12 µM (Tombes et al., 1995).
In addition, cells were treated with the membrane-permeable myristoylatedautocamtide-2-related inhibitory peptide (MyrAIP), which mimics the CaMKII
autoinhibitory domain (Ishida and Fujisawa, 1995) and blocks activity at
concentrations similar to KN-93 (Easley et al., 2006, Easley et al., 2008). Such
treatment resulted similar to the KN-93 treatment in a decreased process index
(Fig. 2.2C). CaMKII inhibition was not found to be associated with a change in
cell viability (KN-92: 100±9%, KN-93: 96±12%).
Morphological maturation of oligodendrocytes occurs as a dynamic process
that is characterized by process extension and retraction events (Kachar et al.,
1986, Fox et al., 2006a). As shown in Fig. 2.2D, process indices were found to
be significantly decreased 2 hours after initial KN93 treatment when compared to
the process indices found at the beginning of the treatment. Thus, the decreased
morphological maturation seen in response to CaMKII inhibition is likely due to
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an increase in process retraction events rather than an inhibition of process
outgrowth.
Retraction of cellular processes has been associated with de-stabilization of
the actin cytoskeleton (Easley et al., 2006) Since KN-93 has been well described
to inhibit not only CaMKII’s kinase catalytic but also CaMKIIβ’s actin
binding/stabilizing activity (Fig. 2.2G; (Sumi et al., 1991, Lin and Redmond,
2008), its use alone precludes an analysis of specifically CaMKIIβ’s actin
binding/stabilizing activity. However and in support of an actin de-stabilizing
effect of KN-93 treatment in differentiating oligodendrocytes, co-treatment with
jasplakinolide, which specifically and rapidly blocks actin filament disassembly
(Boggs and Wang, 2004), abolished the effect of KN-93 on the oligodendrocyte’s
process network (Fig. 2.2E,F). No evidence for a change in cellular viability was
noted.

Downregulation of Camk2b expression restrains the morphological
maturation of differentiating oligodendrocytes
To determine the extent to which specifically CaMKIIβ may be involved in
regulating the morphology of the oligodendrocyte’s process network, an siRNAmediated gene silencing approach was used. As shown in Fig. 2.3A,B, treatment
with an siRNA pool to Camk2b led to a significantly decreased process index.
Under the conditions used, siRNA treatment resulted in significantly reduced
mRNA levels for Camk2b (Fig. 2.3C), Camk2a (60±4%) and Camk2d (74±9%).
Use of an siRNA pool to Camk2g served as a control since expression of
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Camk2g was undetectable in our original analysis (Fig. 2.1A). For cells treated
with the siRNA pool to Camk2b, a reduction in CaMKIIβ protein levels could also
be confirmed (Fig. 2.3C, inset). In neither case, was the gene-specific
downregulation of Camk2 expression associated with an increase in mRNA
levels for any of the other Camk2 genes (data not shown).
In vivo, morphological maturation of oligodendrocytes is associated with well
described changes in gene expression (Pfeiffer et al., 1993; Baumann and
Pham-Dinh, 2001; Emery, 2010). Under experimental conditions, however,
molecular mechanisms regulating cellular morphology may be uncoupled from
those that regulate gene expression (Buttery and ffrench-Constant, 1999,
Osterhout et al., 1999, Kim et al., 2006, Lafrenaye and Fuss, 2010). To
investigate a potential role of Camk2b in regulating gene expression in
differentiating oligodendrocytes, expression levels for mRNAs encoding the
major myelin genes myelin basic protein (Mbp) and proteolipid protein (Plp)
(Fulton et al., 2010) were determined. No significant differences were noted (Fig.
2.3D). In addition, no difference was noted in the percentage of O4-positive cells
that were also immuno-positive for MBP (siControl 52±4%, siCamk2b 49±2%).

Systemic knock-out of Camk2b leads to significantly reduced myelination
To determine the extent to which Camk2b may regulate developmental
myelination in vivo, ventral spinal cords of systemic Camk2b knock-out (Camk2b/-

) mice (van Woerden et al., 2009) were analyzed. As shown in Fig. 2.4A-C, the

myelin sheath g-ratio (axon diameter divided by the diameter of the entire
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myelinated fiber) was significantly increased at postnatal day 21 (P21) in
Camk2b-/- spinal cords. This effect on myelin thickness persisted up to at least 58
days of age (Fig. 2.4D,E) and was not associated with significant changes in the
number of myelinated axons (P21: WT 39±2/14.6µm2, Camk2b-/- 41±2/14.6µm2;
P58: WT 35±2/14.6µm2, Camk2b-/- 35±1/14.6µm2) or apparent signs of axonal
damage (Fig. 2.4A). In addition, no significant changes in the number of
oligodendrocytes were noted (P21: WT 100±6%, Camk2b-/- 112±5%).
To

assess

whether

the

mechanism

by

which

CaMKIIβ

regulates

oligodendrocyte maturation and CNS myelination may be mediated by a nonenzymatic activity, developmental myelination was assessed in Camk2bA303R
mutant mice. In these mice the wild-type Camk2b gene has been replaced by the
mutated Camk2bA303R gene (Borgesius et al., 2011). This mutation has been
characterized to lead to a loss of calcium/calmodulin binding and kinase catalytic
activation but to preserve the ability of CaMKIIβ to bind to and bundle/stabilize
actin filaments (Shen and Meyer, 1999, Fink et al., 2003, O'Leary et al., 2006, Lin
and Redmond, 2008). As shown in Fig. 2.4F,G, Camk2bA303R mutant mice were
devoid of the deficits in myelin thickness seen in Camk2b-/- mice.

Discussion
Using in vitro tissue culture as well as in vivo knock-out and knock-in strategies,
we identified CaMKIIβ as a critical component of the molecular mechanism
regulating oligodendrocyte maturation and CNS myelination. More specifically,
our data point toward a role of CaMKIIβ in regulating the oligodendrocyte’s actin
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cytoskeleton via a mechanism that may not require its kinase catalytic activity but
may instead involve its actin binding/stabilizing activity.
Our in vivo analysis of developmental myelination demonstrates that CaMKIIβ
is involved in the regulation of myelin thickness. Taken together with our in vitro
tissue culture studies we propose that this regulatory role of CaMKIIβ is at least
in part mediated by an oligodendrocyte-autonomous mechanism. In support of
this idea, astrocytes are considered to not express considerable levels of
Camk2b (Takeuchi et al., 2000, Vallano et al., 2000). In addition, CaMKIIβ
protein levels in axons located within the ventral spinal cord have been described
to be undetectable or very low (Terashima et al., 1994). Thus, systemic Camk2b
knock-out is unlikely to cause a predominantly axon-mediated effect on
myelination within the CNS region investigated here.
The lack of a myelination deficit in the spinal cord of Camk2bA303R mutant
mice strengthens the idea of a functional role of CaMKIIβ as an actin regulatory
protein and via its actin binding activity. In neuronal dendritic spines, CaMKIIβ,
via its actin binding activity, is thought to stabilize the actin cytoskeleton and thus
overall spine shape. At the same time, however, calcium signaling has been
implicated in promoting release of CaMKIIβ from the actin cytoskeleton and to
thereby open a time window during which actin cytoskeleton remodeling events
are favored (Okamoto et al., 2007; Okamoto et al., 2009). In analogy,
oligodendrocyte maturation and CNS myelination may be regulated by CaMKIIβmediated alternating cycles of actin cytoskeleton stabilization and destabilization/remodeling. As CaMKIIβ-mediated regulation is dependent on
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calcium signaling events, it is worth mentioning that an increase in calcium
signaling has been reported to stimulate oligodendrocyte process outgrowth and
thus morphological maturation (Yoo et al., 1999). Furthermore, it has been
recently shown that balanced activation and de-activation of the actin filament
severing and depolymerizing factor cofilin regulates Schwann cell function during
peripheral nervous system myelination (Sparrow et al., 2012). This finding
supports the idea that efficient myelination may be critically dependent on a wellbalanced equilibrium between dynamic remodeling and kinetic stability of the
actin cytoskeleton. Future studies will, however, be necessary to better define the
role of CaMKIIβ in regulating the actin cytoskeleton during oligodendrocyte
maturation and CNS myelination.
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Figure 2.1 In differentiating oligodendrocytes Camk2b is the predominantly
expressed Camk2 gene. A, Alternative splicing profile of oligodendrocyte-derived
Camk2 genes as determined by RT-PCR analysis. Conserved non-alternatively
spliced “linker” exons within the variable region are depicted as black boxes
labeled with the roman numerals II and VII. Alternatively spliced exons are
depicted as white boxes labeled with roman numerals. Lines indicate alternative
splicing events. P1 and P2 indicate the locations of the two primers used for RTPCR amplification. B, Camk2 mRNA expression levels as determined by qRTPCR analysis. For the bar graph, total Camk2 mRNA levels were set to 100%
and the values for each of the three genes were adjusted accordingly. Data
represent means ± SEM (n = 3 independent experiments, *p<0.05, Student’s ttest).
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Figure 2.2 Inhibition of CaMKII activity in differentiating oligodendrocytes
restrains the establishment of an expanded process network. A,F,
Representative images of differentiating oligodendrocytes immunostained with
the O4 antibody and treated for 6 hours as indicated. Scale Bars: 20 µm. B-E,
Bar graphs representing quantitative analyses of process indices as described by
Dennis et al. (2008). Cells in B,D,E were treated with the pharmacological
CaMKII inhibitor KN-93 or its inactive derivative KN-92 as control, while cells in C
were treated with the myristoylated autoinhibitory CaMKII peptide (Myr-AIP) or a
myristoylated control peptide (CtrlP). Cells in E were co-treated with the actin
stabilizing peptide jasplakinolide (10 µM) where noted and analyzed after 6 hours
of treatment. Otherwise, final concentrations and duration of treatments are
indicated within the bar graphs. In B,C,E experimental conditions were compared
to control-treated cells cultured for an equivalent period of time. In D,
experimental conditions were compared to control-treated cells at time-point 0.
For all bar graphs, the mean values for control cells were set to 100% (horizontal
grey line) and experimental values were calculated accordingly. At least 25 cells
per condition and experiment were analyzed in three independent experiments (=
total of at least 75 cells per condition). Data represent experimental means ±
SEM (*p<0.05, Student’s t-test). G, Representative images of CIMO cells
transfected with a plasmid encoding GFP-CaMKIIβ and stained for F-actin
(phalloidin). Scale Bars: 5 µm.
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Figure 2.3 Knock-down of Camk2b expression in differentiating oligodendrocytes
restrains the establishment of an expanded process network. A, Bar graph
representing quantitative analyses of process indices (Dennis et al., 2008) upon
siRNA-mediated knock-down of individual Camk2 genes as indicated. The mean
value for cells treated with the control siRNA pool was set to 100% (horizontal
grey line) and experimental values were calculated accordingly. At least 25 cells
per condition and experiment were analyzed in four independent experiments (=
total of at least 100 cells per condition). Data represent experimental means ±
SEM (*p<0.05, Student’s t-test). B, Representative images of differentiating
oligodendrocytes immunostained with the O4 antibody and treated with a control
(siControl) or Camk2b-specific (siCamk2b) siRNA pool. Scale Bars: 20 µm. C,
Bar graph depicting the Camk2b mRNA level upon siRNA-mediated knock-down
of Camk2b. The mean value for cells treated with the control siRNA pool was set
to 100% (horizontal grey line) and the experimental value was calculated
accordingly. The experimental mean ± SEM (*p<0.05, one sample t-test) is
shown. The inset depicts a representative Western blot. CaMKIIβ and GAPDH
protein levels are shown for cells treated with a control (siControl) or Camk2bspecific (siCamk2b) siRNA pool. D, Bar graph depicting Mbp (total and exon 2
containing) and Plp mRNA levels upon siRNA-mediated knock-down of Camk2b.
The mean value for cells treated with the control siRNA pool was set to 100%
(horizontal grey line) and experimental values were calculated accordingly. Data
represent experimental means ± SEM (*p<0.05, one sample t-test).
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Figure 2.4 Knock-out of Camk2b leads to an increase in the g-ratio (decrease in
the thickness) of the myelin sheath, while myelination appears unaffected in
Camk2A303R mutant mice. A, inset in F, Representative electron micrographs of
the ventral spinal cord of 21-day-old (P21) wild-type (WT) and Camk2b knock-out
(Camk2b-/-) mice (in A) or Camk2A303R mutant mice (in F). Scale bars: 1mm.
B,D,F, Scatter plots depicting g-ratios versus axon diameters for P21 Camk2b-/(B), adult Camk2b-/- (D) or P21 Camk2A303R (F) (black filled circles) and WT
littermate (red open circles) ventral spinal cords. The lines represent linear fits to
pooled data from all mice for each genotype. 100 axons per animal were
measured and 3 animals per genotype were analyzed. C,E,G, Bar graphs
depicting average slopes (g-ratio versus axon diameter) and average g-ratios
from individual animals (n=3). Stars indicate statistically significant differences
between wild-type and knock-out/mutant mice (*p < 0.05, Student’s t-test).
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Introduction to Glutamate and Glutamate Transporters
Glutamate transporters and receptors in oligodendrocytes
Glutamate is a major excitatory neurotransmitter found in the CNS that
governs a wide variety of activities from normal brain function to the development
of cells in the CNS (Gallo and Ghiani, 2000, Kukley et al., 2007, Bakiri et al.,
2009, Hamilton et al., 2010). During development, there are multiple sources of
glutamate released in the CNS that could affect cells of the oligodendrocyte
lineage. These sources range from cells such as unmyelinated axons and
astrocytes to extracellular lipids and proteins such as prostaglandins and
neuropeptides respectively (Parpura et al., 1994, Gallo et al., 1996, Gallo and
Ghiani, 2000, Bezzi and Volterra, 2001, Kukley et al., 2007, Ziskin et al., 2007,
Nave and Trapp, 2008, Bakiri et al., 2009, Hamilton et al., 2010). Glutamate
release and signaling in oligodendrocytes are key in many aspects of
oligodendrocyte progenitor migration, proliferation, and differentiation (Barres
and Raff, 1993, Gallo et al., 1996, Ziskin et al., 2007, DeSilva et al., 2009).
In general, glutamate signals through the activation of specific glutamate
receptors. These receptors are divided into metabotropic and ionotropic
receptors. Metabotropic glutamate receptors are further subdivided into classes
based on activation or inhibition of downstream proteins such as phospholipase
C and adenylate cyclase (Bakiri et al., 2009, Martinez-Lozada et al., 2011).
However, metabotropic receptors seem to be downregulated early on in
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oligodendrocyte differentiation and maturation (Deng et al., 2004, Luyt et al.,
2007).
Examples of ionotropic receptors are N-methyl-D-aspartate (NMDA), αamino-3-hydroxy-5-methyl-4-isoxazolepropionic acid receptor (AMPA), and
Kainate receptors. All types of ionotropic receptors are expressed during
oligodendrocyte differentiation. Although NMDA receptors and AMPA receptors
are usually associated with neurons, they also play a critical role in mediating
glutamate signaling and excitotoxicity in oligodendrocytes (Verkhratsky and
Kirchhoff, 2007).
Oligodendrocytes express AMPA receptors in immature oligodendrocytes
and mature oligodendrocytes throughout the brain (Gallo and Ghiani, 2000,
Verkhratsky and Steinhauser, 2000, Verkhratsky and Kirchhoff, 2007). Activation
2+

of AMPA receptors in oligodendrocytes produces substantial Ca
2+

increase in cytosolic Ca

influx and an

signals in culture and acute brain slices (Burnashev et

al., 1992; Verkhratsky and Kirchhoff, 2007).
NMDA receptors are expressed in oligodendrocytes in the corpus
callosum, cerebellum, and optic nerve (Karadottir et al., 2005, Salter and Fern,
2005, Micu et al., 2006). They are glutamate-gated ion channels formed by
oligomeric subunits (Wong, 2006), consisting of a NR1 subunit and various types
of NR2 subunits. Both of these subunit types have been found in
oligodendrocytes (Wong, 2006). In particular, the NR2 subunits NR2A, NR2B,
NR2C, and NR2D are expressed in oligodendrocytes (Wong, 2006).
Quantification of the subunit population in oligodendrocytes shows that NR1,
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NR2C, and NR3A are the most abundant subunits in the optic nerve. NR2B
subunits are present, although not as abundant (Wong, 2006).
With regard to their subcellular localization, NMDA receptors are found
primarily in the cellular process of oligodendrocytes where they are thought to
mediate responses that develop in the distal processes (Salter and Fern, 2005,
Micu et al., 2006). They are much less prominent in the soma of
oligodendrocytes (Micu et al., 2006; Salter and Fern, 2005).
By using electrophysiological recordings, research has shown the activation
of NMDA receptors during all stages of the oligodendrocyte lineage (Karadottir et
al., 2005). Although the function of NMDA receptors in oligodendrocytes is
unclear, NMDA receptors are suggested to play a role in the targeting and
interaction of the axon with the oligodendrocyte process (Salter and Fern, 2005;
Verkhratsky and Kirchhoff, 2007; Wong, 2006).
Contradictory to the role NMDA receptors play during development, studies
have shown that oligodendrocyte specific knockout of NMDA receptors NR1
subunit (which in turn functionally inactivates NMDA receptors) leads to normal
physiology, morphology, numbers, and myelination of oligodendrocytes (De
Biase et al., 2011, Guo et al., 2012). This brings into question the importance of
NMDA receptors during development. De Biase et.al (2011) observed an
increased expression of AMPA receptors after NMDA knockout. This observed
increase in AMPA receptors could provide a compensatory response to the
NMDA knockout (De Biase et al., 2011). In addition to a potential role during
development, activation of NMDA receptors has also been found to lead to rapid

65

cell death during ischemic attacks by mediating excitotoxicity (Salter and Fern,
2005; Verkhratsky and Kirchhoff, 2007; Wong, 2006). Thus, the functional role of
NMDA receptors may be more prominent under pathological conditions than
during development.
Glutamate can activate other types of glutamate responsive transmembrane
proteins. These proteins belong to a family of electrogenic sodium-dependent
transporters. These transporters have been well characterized to remove
glutamate from the extracellular environment (Domercq et al., 1999, DeSilva et
al., 2009, Martinez-Lozada et al., 2011). The glutamate transporter family has
five genes in mammals: excitatory amino acid transporters 1-5 (Eaat1-Eaat5);
however, oligodendrocytes have been characterized to express three of these
genes: Eaat1-Eaat3. These subtypes are also named glutamate aspartate
transporter (GLAST), glutamate transporter 1 (GLT1), and EAAC1 respectively.
(Domercq et al., 1999, DeSilva et al., 2009, Martinez-Lozada et al., 2011, Lee et
al., 2012).
Several studies have examined the expression and the functional role of
sodium-dependent glutamate transporters as they relate to oligodendrocyte
development. A study using transgenic mice for each promoter of GLT1 and
GLAST focused on the cellular identification of these glutamate transporters in
different cell types of the CNS. The study used reporter mice and showed that
GLT1 promoter activity is in the adult and for the most part restricted to
astrocytes. GLAST promoter activity was, however, also seen in
oligodendrocytes in the white matter of the spinal cord, striatum, and corpus
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callosum (Regan et al., 2007). Furthermore, this study demonstrated by
functional uptake experiments that oligodendrocytes likely express more than
one glutamate transporter (Regan et al., 2007). This was furthermore
demonstrated in a later study showing that all three transporters are found in rat
oligodendrocytes in vitro. Not only were they found present in oligodendrocytes,
they were also found to be functionally active with EAAC1 apparently possessing
the highest uptake activity (DeSilva et al., 2009). Based on these studies, the
functional activity of these transporters appeared to be similar in the uptake
capacity and the affinity for glutamate as seen for astrocytes (DeSilva et al.,
2009). In several studies, protein expression of each transporter was seen at
varying stages of the oligodendrocyte lineage (DeSilva et al., 2009). Interestingly,
GLT1 expression seems to be upregulated as oligodendrocyte development
progresses from pre-oligodendrocytes to mature oligodendrocytes (DeSilva et al.,
2009). However, in vivo, there seems to be a downregulation of GLT1 in more
mature (P20) rat corpus callosum. This is in contrast to slight differences in
expression profiles when comparing cells in culture to in vivo tissues. All three
subtypes of transporters are expressed by oligodendrocytes (Domercq et al.,
1999, DeSilva et al., 2009, Martinez-Lozada et al., 2011).
In addition to glutamate clearance, research suggests that glutamate
transporters could play a role in downstream signaling mechanisms. Activation of
glutamate transporters allows for glutamate to enter the cell through the
transporter’s pore. Along with the entrance of glutamate, 3 Na+ ions also pass
through the transporter and enter the cell. This influx of sodium can activate the
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reverse mode of the Na+/Ca2+ exchanger (NCX) (Martinez-Lozada et al., 2011,
Boscia et al., 2012b). This exchanger then takes the 3 Na+ ions out in exchange
for Ca2+. Thus, activation of glutamate transporters can induce a Ca2+ influx into
the cell (Martinez-Lozada et al., 2011, Boscia et al., 2012b). This Ca2+ influx has
been shown in Bergmann glia cells to initiate signaling cascades (MartinezLozada et al., 2011). Oligodendrocytes express NCX1 and NCX3 and their
expression seems to be developmentally regulated with NCX1 being
downregulated and NCX3 being upregulated as oligodendrocytes mature (Boscia
et al., 2012b) (Figure 3.1). Furthermore, the expression of NCX3 seems to be
crucial for proper myelination and oligodendrocyte development (Boscia et al.,
2012b). Thus the importance of glutamate transporters and its association with
NXC may be critical for proper oligodendrocyte development.

68

Figure 3.1: The transport of glutamate through the glutamate transporter is
coupled to the Na+/Ca2+ exchanger regulating the Na+ efflux in exchange for Ca2+
influx, which can provide localized Ca2+ signaling. Adapted from (MartínezLozada et al., 2011).

69

70

CHAPTER 4
Activation of Sodium-dependent Glutamate Transporters regulates
Oligodendrocyte Maturation via signaling through CaMKIIβ’s Actin
Binding/Stabilizing Domain
(This chapter was submitted to Glia for peer review in July 2013. This work was
an equal contribution between Zila Martinez Lozada and myself. )

INTRODUCTION
Glutamate, the major excitatory amino acid, mediates a wide variety of cellular
responses in the developing and adult central nervous system (CNS), not only by
affecting signal transduction in neurons but also by regulating glia cells, including
the myelinating cells of the CNS, oligodendrocytes (Bakiri et al., 2009,
Kolodziejczyk et al., 2010). Interestingly, the primary mode of glutamate release
affecting differentiating cells of the oligodendrocyte lineage during development
and under physiological conditions appears to be vesicle exocytosis along
unmyelinated axons (Kukley et al., 2007, Ziskin et al., 2007), even though
glutamate release from active axons by reversal of glutamate uptake has also
been proposed (Kriegler and Chiu, 1993). The prominent release of glutamate
from unmyelinated axons raises the possibility that glutamate, in addition to
mediating signaling events at synaptic junctions between NG2-positive glial
progenitors and axons, may be able to trigger transient cellular responses in
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differentiating

oligodendrocytes

that

are

involved

in

the

regulation

of

oligodendrocyte maturation and myelination.
Cells of the oligodendrocyte lineage have been described to express
members of all of the three major glutamate-responsive transmembrane protein
families, namely ionotropic and metabotropic glutamate receptors as well as
sodium-dependent glutamate transporters (Kolodziejczyk et al., 2010, Matute,
2011). Out of these, metabotropic glutamate receptors have been found
downregulated as oligodendrocytes differentiate (Deng et al., 2004, Luyt et al.,
2006), and ionotropic glutamate receptors have been primarily implicated in
mediating excitotoxicity (Matute, 2011). Thus, sodium-dependent glutamate
transporters emerge as good candidates for mediating glutamate-evoked
responses related to the maturation of differentiating oligodendrocytes, i.e. of
cells that are located in the vicinity of axonal segments to be myelinated and that
are beyond the progenitor stage. Of the known five mammalian sodiumdependent glutamate transporters, also known as excitatory amino acid
transporters (EAAT) or members of the solute carrier family 1 (SLC1), three have
been found expressed by cells of the oligodendrocyte lineage, namely GLAST
(EAAT1, SLC1A3), GLT-1 (EAAT2, SLC1A2) and EAAC1 (EAAT3, SLC1A1)
(Domercq and Matute, 1999, Regan et al., 2007, Arranz et al., 2008, DeSilva et
al., 2009, Kukley et al., 2010, Lee et al., 2012). These transporters have been
well characterized to remove the excitatory amino acid glutamate from the
extracellular environment (Danbolt, 2001, O'Shea, 2002, Beart and O'Shea,
2007). However, there is increasing evidence for a role of sodium-dependent
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glutamate transporters beyond extracellular glutamate clearance (Chen et al.,
2006, Martinez-Lozada et al., 2011, Lopez-Colome et al., 2012).
Interestingly, signaling initiated by the activation of sodium-dependent
glutamate transporters has been proposed to activate calcium/calmodulindependent kinase type II (CaMKII) (Martinez-Lozada et al., 2011), and one of the
four CaMKII genes, namely CaMKIIβ, has recently been implicated in the
regulation of oligodendrocyte maturation and myelination (Waggener, 2013
#1214). More specifically, CaMKIIβ has been proposed to promote the
morphological aspects of oligodendrocyte maturation, which are to a large extent
regulated by changes in the cellular cytoskeleton (Bauer et al., 2009), primarily
via its actin binding/stabilizing domain rather than its well-known kinase catalytic
domain (Waggener et al., 2013). Thus and based on the above observations, we
investigated here a possible role of a glutamate transporter-CaMKIIβ-actin
cytoskeleton

axis

in

the

regulation

of

the

morphological

aspects

of

oligodendrocyte maturation.

MATERIALS AND METHODS
Animals
Sprague–Dawley female rats with early postnatal litters were obtained from
Harlan Laboratories, Inc. (Indianapolis, IN). All animal studies were approved by
the Institutional Animal Care and Use Committee at Virginia Commonwealth
University.
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Antibodies
Supernatants from cultured hybridoma cells (clone A2B5; ATCC, Manassas, VA)
were used for immunopanning. Anti-GLAST, anti-GLT-1, anti-EAAC1 (Abcam,
Cambridge, MA), anti-CaMKII, anti-pCaMKII T286/7 (Cell Signaling Technology,
Inc. Danvers, MA) and anti-GAPDH (EMD Millipore, Billerica, MA) antibodies in
combination with horseradish peroxidase (HRP)-labeled secondary antibodies
(Vector Laboratories, Burlingame, CA) were used for Western blot analysis.
Antibodies specifically recognizing pCaMKIIβ S371 were generated and
characterized by us. Supernatants from cultured hybridoma cells (clone O4; gift
from S.E. Pfeiffer) and anti-MBP antibodies (EMD Millipore, Billerica, MA) were
used for immunocytochemistry to identify post-migratory, premyelinating
oligodendrocytes (Sommer and Schachner, 1981, Bansal et al., 1989) and later
stages of the oligodendrocyte lineage, respectively. Alexa 488- or Alexa 564conjugated antibodies (Life Technologies, Grand Island, NY) were used as
secondary antibodies.

Cell Culture
Primary rat oligodendrocyte progenitors were isolated from postnatal day 3 (P3)
rat brains by A2B5 immunopanning (Lafrenaye and Fuss, 2011, Barres, 1992
#57). Oligodendrocyte progenitors were either used directly in plasmid
nucleofection experiments or plated onto fibronectin (10 µM/mL)-coated tissue
culture dishes or glass coverslips. Plated oligodendrocyte progenitors were then
cultured in serum-free differentiation medium (DMEM containing 40 ng/ml tri-
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iodo-thyronine (T3; Sigma, St Louis, MO) and 1x N2 supplement (Life
Technologies Corp., Grand Island, NY); DMEM/T3/N2). In siRNA-mediated gene
silencing experiments, differentiating oligodendrocytes were transfected with
siRNAs 24h after plating. Otherwise, plated oligodendrocyte progenitors were
allowed to differentiate for 48h. Under these conditions, the majority of cells
represented post-migratory, premyelinating oligodendrocytes as they expressed
the O4 antigen (Sommer and Schachner, 1982, Warrington et al., 1993)(data not
shown). Such populations of differentiating oligodendrocytes were then either
directly analyzed or treated with L-glutamate (Glu; R&D Systems, Inc.
Minneapolis, MN), D-aspartate (Asp; R&D Systems, Inc. Minneapolis, MN), the
competitive, non-transportable blocker of excitatory amino acid transporters
TBOA (R&D Systems, Inc. Minneapolis, MN), the membrane permeable
pharmacological inhibitor of CaMKII activity KN-93 or the inactive derivative of
KN-93, KN-92 (EMD Millipore, Billerica, MA) as indicated. In the case of dual
treatments, TBOA, KN-93 or KN-92 were added 30 min prior to the application of
L-glutamate or D-aspartate. Cells were analyzed 6 hours after addition of Lglutamate or D-aspartate unless stated otherwise.
Cells of the immortalized mouse oligodendroglial cell line CIMO were cultured
in DMEM/5% FCS/1 µg/mL interferon-γ (EMD Millipore, Billerica, MA) at 33 °C
(Bronstein et al., 1998) and then used in plasmid nucleofection experiments.

Quantitative (q)RT-PCR Analysis
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Total RNA was isolated from oligodendrocyte cultures using the RNeasy Micro
Kit (QIAGEN Inc., Valencia, CA). Purified RNA samples were quantified using the
Nanodrop ND-1000 (Nanodrop Inc., Wilmington, DE) and oligo(dT)/random
hexamer-primed cDNAs were synthesized using the Omniscript RT kit (QIAGEN
Inc., Valencia, CA). qRT-PCR was performed on a CFX96 Real-Time PCR
Detection System (Bio-Rad, Hercules, CA) using the iQ SYBR Green Supermix
(Bio-Rad, Hercules, CA) and the following gene-specific primer pairs:
Glast:

forward

(5′-AGCCTGGGGTGTCTTCCACCA-3′),

reverse

(5′-

reverse

(5′-

reverse

(5′-

ACCACAGCCTTGCACTTCAGTGTCT-3′);
Glt-1:

forward

(5′-TGGCGGCTCCCATCCACCCT-3′),

GGCGGCCGCTGGCTTTAGCA-3′);
Eaac1:

forward

(5′-GCCCACGAGCTCGGGATGCG-3′),

CACGATGCCCAGTACCACGGC-3′).
Ppia (reference gene):

forward: (5′-GGAGACGAACCTGTAGGACG-3′) and

reverse: (5′-GATGCTCTTTCCTCCTGTGC-3’)
Pgk1 (reference gene):

forward:

(5’-ATGCAAAGACTGGCCAAGCTAC-3’)

and reverse: (5’-AGCCACAGCCTCAGCATATTTC -3’)
PCR conditions were as follows: 95°C for 3 min followed by 40 cycles of 95°C
for 15s, 58°C for 30s, and 95°C for 10s. For comparing the expression levels of
the different genes, R0 values were determined as described by (Peirson et al.,
2003). To determine relative expression levels the ΔΔCT method was used (Livak
and Schmittgen, 2001).
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Western blot analysis
Cells were homogenized in lysis buffer (150 mM NaCl, 10 mM KCl, 20 mM
HEPES (pH 7.0), 1 mM MgCl2, 20% Glycerol, 1% Triton X-100) including the
complete protease and phosphatase inhibitor cocktail (Thermo Scientific,
Rockford, IL). Protein concentrations were determined using the micro BSA
protein assay kit (Thermo Scientific, Rockford, IL). 12µg of protein were used for
Western blot analysis (except when using anti-GLAST antibodies, in which case
30µg of protein were used). All samples were diluted 1:2 in Laemmli Sample
Buffer (Bio-Rad, Hercules, CA) and denatured by a 5 min incubation at 95°C.
Proteins were resolved on 10% SDS–polyacrylamide gels (Mini-Protean TGX
Gels, Bio-Rad, Hercules CA) and then transferred to Immobilon-P PVDF
membranes (EMD Millipore, Billerica, MA). Membranes were incubated in 5-10%
fat-free milk powder in TBS-T (10 mM Tris–HCl, pH 7.5, 0.15 M NaCl, 0.2%
Tween 20) for 60 min to block the excess of non-specific protein binding sites.
Membranes were then incubated overnight at 4°C with primary antibodies as
indicated. Bound antibodies were detected using HRP-conjugated secondary
antibodies in combination with the ECL Prime Western blotting detection reagent
(GE Healthcare Life Sciences, Piscataway, NJ). Chemiluminescent signals were
detected by exposure of photographic film (Kodak BioMax MR, Eastman Kodak
Company, Rochester, NY) and quantified by densitometry using the ImageJ
software package (Abramoff et al., 2004).

Immunocytochemistry

77

For immunocytochemistry using O4 hybridoma supernatants, cells were fixed in
a solution containing 4% paraformaldehyde, nonspecific binding sites were
blocked using a solution of 10% FCS in DMEM and cells were incubated with the
supernatant (1:1 diluted in 10%FCS/DMEM) overnight. For immunocytochemical
detection of MBP, cells were fixed in a solution containing 4% paraformaldehyde
and then permeabilized using 0.5% Triton X-100/0.4 M sucrose in PBS.
Subsequently, cells were incubated for 30 min in 10% FCS/DMEM and then
overnight with anti-MBP antibodies (SMI99; Covance, Princeton, NJ) (1:250
diluted in 10% FCS/DMEM). Primary antibodies were detected using Alexa 488or Alexa 564-conjugated secondary antibodies (Life Technologies Corp., Grand
Island, NY) (1:250 diluted in PBS) and nuclei were counterstained using Hoechst
(1 µg/mL; EMD Millipore, Billerica, MA).
To visualize the actin cytoskeleton, cells were fixed in a solution containing
4% paraformaldehyde, 0.5 % glutaraldehyde and 0.4M sucrose and then
incubated with Acti-stain 555 phalloidin (Cytoskeleton, Inc., Denver, CO).

siRNA-mediated Gene Silencing
Differentiating oligodendrocytes were transfected with ON-TARGETplus siRNA
SMARTpools directed against rat Glast, Glt-1 or Eaac1 (Thermo Fisher Scientific
Inc., Pittsburg, PA) using Lipofectamine 2000 (Life Technologies Corp., Grand
Island, NY). As control, an ON-TARGETplus non-targeting siRNA pool (Thermo
Fisher Scientific Inc., Pittsburg, PA) was used. Transfection medium containing
siRNA-Lipofectamine complexes was replaced with serum-free differentiation
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medium (DMEM/T3/N2) after 3h and cells were cultured for an additional 72h.
Knock-down of gene expression was assessed by qRT-PCR and Western blot
analysis.

Process Morphology Analysis
Oligodendrocyte morphology was analyzed as previously described (Dennis et
al., 2008). Briefly, oligodendrocytes were immunostained using O4 hybridoma
cell supernatants. Images of approximately 30 cells were taken randomly for
each treatment group in each experiment (n≥3) using an Olympus BX51 inverted
fluorescent microscope (Olympus America Inc., Center Valley, PA). IP Lab
imaging software (BD Biosciences Bioimaging, Rockville, MD) was used to
determine process index (total O4 imunopositive area minus the cell body) and
network area (total area within the radius of the O4 immunopositive process
network minus the cell body). For the bar graphs representing network area, the
mean value for cells cultured under control conditions was calculated. This mean
value was set to 100% and adjusted, i.e. normalized, values for all cells were
averaged for each experimental condition. For the generation of representative
images, confocal laser scanning microscopy was used (Zeiss LSM 510 META
NLO; Carl Zeiss Microscopy, LLC, Thornwood, NY). Images represent 2D
maximum projections of stacks of 0.4 µm optical sections.

Cell Count Analysis
Images of four fields were taken with a 20x objective from each coverslip (three
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coverslips per condition) using an Olympus BX51 fluorescence microscope
equipped with an Olympus DP72 CCD camera (Olympus America Inc., Center
Valley, PA). The number of Hoechst-positive and MBP immuno-positive
oligodendrocytes was then determined using the Cell Counter plugin to the
ImageJ software package (Abramoff et al., 2004).

Plasmid Nucleofection
A2B5 immunopanned oligodendrocyte progenitors or CIMO cells were
nucleofected (Lonza Cologne GmbH, Cologne, Germany) with the following
constructs: a plasmid encoding eGFP-CaMKIIβ (Okamoto et al., 2004), a plasmid
encoding eGFP-CaMKIIβallA in which all serine and threonine residues located
within the variable domain (aa 317-396) were replaced with alanine, a plasmid
encoding eGFP-CaMKIIβallD in which all serine and threonine residues located
within the variable domain (aa 317-396) were replaced with aspartic acid, and a
control plasmid encoding eGFP alone. All plasmids had the same plasmid
backbone derived from the eukaryotic expression vector pEGFP-C1 (Clontech
Laboratories, Inc., Mountain View, CA).

Intracelullar Calcium Measurement
Intracellular calcium concentrations were determined in principle as previously
described (Grynkiewicz et al., 1985). Briefly, differentiating oligodendrocytes
were loaded with the calcium indicator fura-2 AM ester (2.5µM) and pluronic
(0.01%) (Life Technologies Corp., Grand Island, NY) in differentiation medium for
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30 min at 37°C. Cells were washed and incubated in differentiation medium for
an additional 30 min at 37°C. Ratiometric calcium measurements were made at
340 and 380 nm excitation and 510-520 nm emission wavelengths with cells
cultured in differentiation medium (unless mentioned otherwise) using a Zeiss
Observer.Z1 microscope in combination with the Axio VisionRel 4.8 software
package (Carl Zeiss Microscopy, LLC, Thornwood, NY). Measurements were
made before and after the application of the indicated compounds. To calculate
intracellular free calcium concentrations (in nM), a calibration curve (Calcium
Calibration Buffer Kit, Life Technologies Corp., Grand Island, NY) was used.

Statistical Analysis
For statistical analysis the GraphPad Prism software (GraphPad Software, Inc.,
La Jolla, CA) was used. In the case of two or more groups of data composed of
variable values, two-tailed Student’s t-tests or Kruskal–Wallis one-way analyses
of variance (ANOVA) combined with post hoc Dunn’s or Student–Newman–Keuls
tests were performed. When comparing a single control group with experimental
groups of data, ANOVA with post hoc Dunnett tests were used. In the case data
were compared to a set control value (1 or 100%) lacking variability, one-sample
t-tests were used (Skokal and Rohlf, 1995, Dalgaard, 2008).

RESULTS
Sodium-dependent glutamate transport, mediated primarily by GLAST and
GLT-1,

promotes

the

morphological

81

maturation

of

differentiating

oligodendrocytes.
As introduced above, the sodium-dependent glutamate transporter genes Glast,
Glt-1and Eaac1 have previously been described to be expressed by cells of the
oligodendrocyte lineage. To confirm such expression in our culture system, qRTPCR analysis was performed and revealed relative mRNA expression levels of
45±5%, 31±6%, and 12±5% for Glast, Glt-1 and Eaac1, respectively (Fig. 4.1A).
Using Western blot analysis the expression of the three sodium-dependent
glutamate transporters in differentiating oligodendrocytes could be further
validated (Fig. 4.1B). To assess a potential role of sodium-dependent glutamate
transport

beyond

extracellular

glutamate

clearance

in

differentiating

oligodendrocytes, these cells were treated with 100 mM L-glutamate in
combination with TBOA, a competitive and non-transportable inhibitor of sodiumdependent glutamate transport (Shimamoto et al., 1998, Shigeri et al., 2001), and
morphological aspects of oligodendrocyte maturation were assessed by
determining the cells’ network areas and process indices (Dennis et al., 2008).
Increases in both parameters were observed upon treatment with L-glutamate
(Fig. 4.2A,B and data not shown). This maturation-promoting effect of Lglutamate was seen as early as 2 hours and up to 6 hours of treatment (Fig.
4.2C). Importantly, it could be blocked by pre-treatment with TBOA and was thus
found to be dependent on the activity of sodium-dependent glutamate
transporters (Figs. 4.2A,B). It is of note that in agreement with previous studies,
no obvious effects on cell survival were noted in the presence of the glutamate
and TBOA concentrations used here and within the time frames analyzed (Deng
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et al., 2006) and data not shown).
To further substantiate that sodium-dependent glutamate transporters play a
predominant role in the observed maturation-promoting effect exerted by Lglutamate, the naturally occurring amino-acid D-aspartate was used as a
glutamate-equivalent agonist. As L-glutamate, D-aspartate is efficiently taken up
through the sodium-dependent glutamate transporter system (Davies and
Johnston, 1976, Danbolt and Storm-Mathisen, 1986, Kanai and Hediger, 1992,
Pines et al., 1992, Palacin et al., 1998), and it is then endogenously metabolized
(Schell et al., 1997). In contrast to L-glutamate, however, D-aspartate is known to
not activate non-NMDA receptor iononotropic glutamate receptors (Domercq et
al., 2005, Errico et al., 2008), thus eliminating potential confounding effects due
to an activation of AMPA/kainate receptors. As shown in Fig. 4.2D, the effect of
D-aspartate on the oligodendrocyte’s process network was comparable to the
effect seen upon treatment with L-glutamate (compare Figs. 4.2B and D).
It

has

been

well

demonstrated

that

morphological

maturation

of

oligodendrocytes occurs during development concurrently with changes in gene
expression (Pfeiffer et al., 1993, Baumann and Pham-Dinh, 2001, Emery, 2010).
Under experimental conditions, however, molecular mechanisms regulating
cellular morphology may be uncoupled from those that regulate gene expression
(Buttery and ffrench-Constant, 1999, Osterhout et al., 1999, Kim et al., 2006,
Lafrenaye and Fuss, 2011, Waggener et al., 2013). Thus and to assess a
potential role of L-glutamate and the activity of sodium-dependent glutamate
transporters on myelin gene expression, potential changes in myelin basic
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protein (MBP) expression were assayed using immunocytochemistry. As shown
in Fig. 4.2E, no significant differences in the number of MBP-positive cells were
noted, thus suggesting that the sodium-dependent glutamate transportermediated effect on oligodendrocyte maturation is primarily associated with the
morphological aspects of this process.
As shown in Fig. 4.1, differentiating oligodendrocytes express more than one
of the known sodium-dependent glutamate transporter genes. To evaluate the
role of individual transporter genes in the L-glutamate-mediated maturationpromoting effect observed here, differentiating oligodendrocytes were transfected
with siRNA pools specifically silencing Glast, Glt-1 or Eaac1 expression. Knockdown of gene expression was confirmed by Western blot analysis, which
revealed a specific reduction in transporter protein levels of at least 70% (Fig.
4.S1). Importantly, for none of the down-regulated genes a compensatory upregulation of any of the other two transporter genes was noted (Fig. 4.S1). As
shown in Fig. 4.2F, knock-down of either Glast or Glt-1 expression was found to
eliminate the effect of L-glutamate on the oligodendrocyte’s process network. For
the sodium-dependent glutamate transporter with much lower expression levels
in differentiating oligodendrocytes when compared with Glast or Glt-1, namely
Eaac1, knock-down of gene expression was seen to only attenuate the effect of
L-glutamate on the oligodendrocyte’s process network (siCtrl+Glu: 157±7%,
siEaac1: 136±6%, p=0.007, ANOVA). Taken together, these data demonstrate
that L-glutamate can promote morphological maturation of differentiating
oligodendrocytes via a sodium-dependent glutamate transporter-mediated
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mechanism. In addition, they suggest that even a slight decline in
oligodendroglial

sodium-dependent

glutamate

transporter

expression

can

significantly reduce the effect of L-glutamate on the morphological maturation of
differentiating oligodendrocytes.

Activation of sodium-dependent glutamate transporters in differentiating
oligodendrocytes leads to a transient increase in intracellular calcium
levels
Having established that activation of sodium-dependent glutamate transporters
promotes the morphological maturation of differentiating oligodendrocytes, we
next wished to explore potential downstream signaling events involved in this
process. These signaling-related studies were focused on calcium-mediated
events, since it had previously been demonstrated that glutamate transport can
activate the reverse mode of the sodium/calcium exchanger and thereby lead to
a transient increase in intracellular calcium levels (Rojas et al., 2007, MartinezLozada et al., 2011, Lopez-Colome et al., 2012). To assess the effect of an
activation of sodium-dependent glutamate transporters on intracellular calcium
levels, D-aspartate was used as a glutamate-equivalent agonist. Using this
strategy, a contribution of AMPA/kainate receptor activation to the observed
transient increase in permeability to calcium (Fig. 4.3) could be excluded. The Daspartate-induced transient increase in free intracellular calcium levels within
differentiating oligodendrocytes was found to be dose-dependent (Fig. 4.3B) and
to be absent in the presence of TBOA (Fig. 4.3C). In addition, no such increase
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was observed in the absence of extracellular calcium (Fig. 4.3B). Taken together,
these data support the idea that in differentiating oligodendrocytes L-glutamate
(as D-aspartate) activates sodium-dependent glutamate transporters which in
turn mediate a transient increase in intracellular calcium levels via entry from the
extracellular environment. Furthermore, it is of note that the D-aspartatemediated transient increase in intracellular calcium levels was observed first
within cellular processes and then within the cell body, thus suggesting that the
sodium-dependent glutamate transporter-evoked intracellular calcium response
may initially occur locally within oligodendrocyte processes.

The

maturation

promoting

effect

of

sodium-dependent

glutamate

transporters in differentiating oligodendrocytes is mediated by a transient
phosphorylation event within CaMKIIβ’s actin binding domain
Our recent data provided good evidence for a critical role of the calcium sensor
CaMKIIβ and in particular its actin binding/stabilizing domain in regulating
oligodendrocyte maturation and myelination (Waggener et al., 2013). Thus,
CaMKIIβ and in particular its actin binding/stabilizing domain may be directly
involved in the sodium-dependent glutamate transporter-mediated effect
described here. Indeed, pre-treatment of differentiating oligodendrocytes with
KN93, a membrane-permeable pharmacological inhibitor of CaMKIIβ’s kinase
catalytic as well as actin binding/stabilizing activity (Lin and Redmond, 2008,
Sumi, 1991 #1025), was found to block the maturation-promoting effect of Lglutamate on the oligodendrocyte’s process network (Fig. 4.4A). It is of note that
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KN93 treatment alone and thus a continuous inhibition of CaMKII activity
attenuated the morphological maturation of differentiating oligodendrocytes (Fig.
4.4A). This effect has been previously described and was found to not be
associated with a change in cellular viability (Waggener et al., 2013).
To further assess the effect of L-glutamate on CaMKII and in particular
CaMKIIβ’s actin binding/stabilizing domain in differentiating oligodendrocytes,
phosphorylation events at CaMKII’s T287/6 and CaMKIIβ’s S371 site were analyzed.
CaMKII’s T287/6 site represents CaMKII’s authophosphorylation site, which due to
sequence conservation could only be detected by pan pCaMKII T287/6 antibodies.
CaMKIIβ’s S371 site is located within CaMKIIβ’s actin binding/stabilizing domain
(Kim et al., 2011), and antibodies specifically recognizing the pCaMKIIβ S371 site
have been generated by us. These antibodies were found to not recognize
CaMKIIβ S371A, a mutant form of CaMKIIβ, which cannot be phosphorylated at its
S371 site (data not shown). As shown in Fig. 4.4B,C, treatment of differentiating
oligodendrocytes with L-glutamate led to a significant increase in phosphorylation
at CaMKIIβ's S371 site. This effect was time-dependent and transient, since an
increase in phosphorylation was not seen prior to 30 min of treatment and at 4
hours

and

beyond

(Fig.

4.4C,F).

Furthermore,

no

such

increase

in

phosphorylation was observed at CaMKII’s autophosphorylation (T286/7) site
within 15-60 min of L-glutamate treatment (Fig. 4.4E), nor was a change in total
levels of CaMKIIβ noted (Fig. 4.4D). Importantly, the effect of L-glutamate on the
phosphorylation at CaMKIIβ's S371 site could be blocked by pre-treatment with
TBOA (Fig. 4.4G), thus demonstrating that activation of sodium-dependent
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glutamate transporters mediates a phosphorylation event within CaMKIIβ's actin
binding/stabilizing domain. To further assess the contribution of individual
sodium-dependent glutamate transporter genes in this L-glutamate-mediated
increase in pCaMKIIβ S371 levels, differentiating oligodendrocytes were
transfected with siRNA pools specifically targeting Glast, Glt-1 or Eaac1
expression. Similar to what was observed for the effect of gene-specific knockdown

of

sodium-dependent

glutamate

transporter

expression

on

the

oligodendrocyte’s network area (Fig. 4.2F), knock-down of Glast or Glt-1
expression eliminated the effect of L-glutamate on the phosphorylation of
CaMKIIβ's S371 site,

while the effect of a knock-down of Eaac1 expression

appeared less pronounced.

Phosphorylation events within CaMKIIβ’s actin binding domain appear to
regulate the association of CaMKIIβ with filamentous F-actin and the effect
of glutamate on the oligodendrocyte’s process network
Our data described so far demonstrated that in differentiating oligodendrocytes,
L-glutamate activates sodium-dependent glutamate transporters, which in turn
mediate a transient increase in intracellular calcium levels, a transient
phosphorylation event at CaMKIIβ’s S371 site and a promotion of the
morphological aspects of oligodendrocyte maturation. In addition, our recent data
demonstrated that upon increases in intracellular calcium levels, serine, including
S371, and threonine residues are phosphorylated within CaMKIIβ’s actin binding
domain, and that these phosphorylation events are sufficient to induce
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detachment of CaMKIIβ from filamentous F-actin (Kim et al., 2011). Taken
together, the above findings raised the possibility that sodium-dependent
glutamate

transporter-mediated

phosphorylation

within

CaMKIIβ’s

actin

binding/stabilizing domain may affect the oligodendrocyte’s process network via
a change in CaMKIIβ’s association with filamentous F-actin. To investigate this
idea, mutant forms of eGFP fusion proteins of CaMKIIβ were generated that
either represented CaMKIIβ in which the serine and threonine residues within in
the

actin

binding/stabilizing

domain

are

non-phosphorylatable

(eGFP-

CaMKIIβallA) or their phosphorylated state is mimicked (eGFP-CaMKIIβallD). In
addition, eGFP-CaMKIIβWT and eGFP-CaMKIIβK43R, a mutant that is impaired in
ATP binding and thus inactive with regard to its kinase catalytic but not actin
binding activity (Okamoto et al., 2007), were used. Consistent with the previously
characterized

role

of

phosphorylation

events

within

CaMKIIβ’s

actin

binding/stabilizing domain on CaMKIIβ’s association with filamentous F-actin,
nucelofection studies using plasmids encoding the above described eGFPCaMKIIβ forms revealed individual subcellular distribution patterns (Fig. 4.5A,B).
More specifically, in cells of the oligodendroglial cell line CIMO, the nonphosphorylatable eGFP-CaMKIIβallA form was found to largely co-localize with
filamentous F-actin (Fig. 4.5A). Similarly, it was detected in differentiating
oligodendrocytes at subcellular locations at which filamentous F-actin has been
previously described to be enriched (Fig. 4.5B), namely within oligodendrocyte
growth cones and at process branching points (Song et al., 2001, Fox et al.,
2006a). In contrast, the phospho-mimetic eGFP-CaMKIIβallD form showed little
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co-localization with filamentous F-actin and appeared similar to eGFP distributed
diffusely and throughout the cytoplasm (Fig. 4.5A,B). In agreement with a likely
only partially phosphorylated state, eGFP-CaMKIIβWT displayed a somewhat
intermediate subcellular distribution (Fig. 4.5A,B). It is of further note that the
eGFP tag used here has been previously shown to not interfere with CaMKIIβ
function (Okamoto et al., 2004, Okamoto et al., 2007).
To correlate the phosphorylation state of CaMKIIβ’s actin binding/stabilizing
domain und thus its level of association with filamentous F-actin with the
morphological maturation of differentiating oligodendrocytes, the effect of the
expression of the different eGFP-CaMKIIβ forms on the oligodendrocyte’s
process network was evaluated. As shown in Fig. 4.5C, expression of the nonphosphorylatable eGFP-CaMKIIβallA form blocked the maturation-promoting
effect of L-glutamate treatment. No such effect was observed when eGFPCaMKIIβWT or eGFP-CaMKIIβK43R were expressed, suggesting that the Lglutamate-mediated maturation-promoting effect may not require CaMKIIβ’s
kinase catalytic activity. Importantly and consistent with our previous findings
(Waggener et al., 2013); Fig. 4.4A), constitutive expression of the phosphomimetic eGFP-CaMKIIβallD form attenuated the morphological maturation of
differentiating oligodendrocytes and eliminated the effect of L-glutamate
treatment on the cell’s process network. Taken together, these data support the
idea that phosphorylation within CaMKIIβ’s actin binding/stabilizing domain
leading to detachment of CaMKIIβ from filamentous F-actin, is a required step in
the mechanism promoting the morphological aspects of oligodendrocyte
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maturation via activation of sodium-dependent glutamate transporters. Notably,
constitutive

(vs.

transient)

phosphorylation

within

CaMKIIβ’s

actin

binding/stabilizing domain appears to have an opposing effect.

DISCUSSION
The study described here, investigated the role of sodium-dependent glutamate
transporters in the regulation of oligodendrocyte differentiation. Our data
demonstrated that activation of in particular GLAST and GLT-1 in differentiating
oligodendrocytes promotes their morphological maturation. On a molecular level,
this

sodium-dependent

glutamate

transporter-mediated

promotion

of

oligodendrocyte maturation was found to be associated with transient increases
in intracellular calcium levels (from the extracellular environment) and
phosphorylation at CaMKIIβ’s S371 site located within CaMKIIβ’s actin
binding/stabilizing domain. In addition, our data revealed a requirement for
phosphorylation events within CaMKIIβ’s actin binding/stabilizing domain. These
phosphorylation events appeared furthermore to regulate CaMKIIβ’s association
with filamentous F-actin. Based on these data and the ascribed function of
CaMKIIβ’s actin binding/stabilizing domain in the regulation of dendritic spine
morphology (Okamoto et al., 2009), we propose the following model for the role
of sodium-dependent glutamate transporters in the regulation of oligodendrocyte
maturation (Fig. 4.6). Under basal conditions, CaMKIIβ is in differentiating
oligodendrocytes to a large extent associated with the actin cytoskeleton.
Glutamate release from for example un-myelinated axonal segments activates

91

oligodendroglial sodium-dependent glutamate transporters, which in turn activate
the reverse mode of oligodendroglial sodium/calcium exchangers resulting in a
transient increase in intracellular calcium levels (Fig. 4.6A). This increase in
intracellular calcium levels leads to phosphorylation events within CaMKIIβ’s
actin binding/stabilizing domain (including CaMKIIβ’s S371 site), inactivation of
CaMKIIβ's actin binding activity and detachment of CaMKIIβ from the actin
cytoskeleton. Such transient inactivation of CaMKIIβ's actin binding activity
opens a time window during which actin cytoskeleton remodeling events and
actin polymerization (Okamoto et al., 2007, Sanabria et al., 2009, Hoffman et al.,
2013) are favored (Fig. 4.6B). This dynamic phase is then followed by a phase of
actin cytoskeleton stabilization via re-activation of CaMKIIβ's actin binding activity
via de-phosphorylation (Fig. 4.6C). It is of note that the actin binding activity of
CaMKIIβ appears to be independent of its kinase catalytic activity, a concept that
is supported by recent in vivo studies (van Woerden et al., 2009, Borgesius et al.,
2011). Also, actin binding properties have been described for other members of
the CaMKII gene family, even though via a different structure-function domain
(Caran et al., 2001, Hoffman et al., 2013). Further studies will be necessary to
evaluate a potential contribution of CaMKII isozymes other than CaMKIIβ in the
molecular mechanism described here. Importantly, constitutive inactivation of
CaMKIIβ's actin binding activity, in contrast to transient inactivation, appears to
attenuate the morphological maturation of differentiating oligodendrocytes, an
effect that is likely mediated by de-stabilization of the actin cytoskeleton over an
extended period of time (Waggener et al., 2013). Thus, it is cycles of activation
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and de-activation of CaMKIIβ’s actin binding activity that allow re-organization of
the actin cytoskeleton and a promotion of the morphological aspects of
oligodendrocyte maturation. This idea is further supported by recent findings
demonstrating that balanced activation and de-activation of the actin filament
severing and depolymerizing factor cofilin regulates the function of the
myelinating cells of the peripheral nervous system, namely Schwann cells
(Sparrow et al., 2012).
Our studies revealed a prominent expression of the sodium-dependent
glutamate transporter gene Glast in differentiating oligodendrocytes. This finding
is in agreement with previous observations made in tissue culture as well as in
vivo in both rodents and humans (Domercq and Matute, 1999, Pitt et al., 2003,
Vallejo-Illarramendi et al., 2006, Regan et al., 2007, DeSilva et al., 2009). In
addition, a low level expression of Eaac1 is consistent with the reported presence
of few Eaac1-positive cells in the developing optic nerve (Domercq and Matute,
1999). In contrast, the expression of Glt-1 in cells of the oligodendrocyte lineage
appears more complicated, since it has in particular in vivo been described to be
developmentally regulated and to be predominant at stages at which
oligodendrocytes are premyelinating (Domercq and Matute, 1999, Desilva et al.,
2007, DeSilva et al., 2009). Our previous data revealed a prominent in vivo role
of CaMKIIβ in the regulation of myelin thickness (Waggener et al., 2013) and
thus likely not only in premyelinating but also myelinating oligodendrocytes.
Thus, a developmentally regulated expression pattern of Glt-1 as described
above would suggests that the signaling pathway proposed here (Fig. 4.6) may in
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vivo be primarily mediated by GLAST and less so by GLT-1. However, in human
tissue the expression of Glt-1 has been reported to occur in mature
oligodendrocytes (Werner et al., 2001, Pitt et al., 2003). Thus, additional studies
will be necessary to more precisely define individual sodium-dependent
glutamate transporter contributions and potential species-specific differences. It
is of further note that while development in mice with single knock-outs for Glast,
Glt-1 or Eaac1 occurs without apparent CNS gross phenotypes (Peghini et al.,
1997, Tanaka et al., 1997, Harada et al., 1998), double Glast/Glt-1 knockout
mice die in utero and show multiple developmental brain defects (Matsugami et
al., 2006). These data indicate that during CNS development the loss of one
sodium-dependent glutamate transporter may functionally be compensated for by
at least one of the remaining transporters, i.e. by a mechanism that could further
complicate a delineation of individual roles for individual sodium-dependent
glutamate transporters.
Our model proposed in Fig. 4.6 is suggestive of pivotal roles for
oligodendroglial sodium/calcium exchangers and intracellular calcium levels in
the regulation of oligodendrocyte maturation. It is thus noteworthy that the
sodium/calcium exchanger NCX3 has recently been implicated in the regulation
of oligodendrocyte differentiation (Boscia et al., 2012a). In addition, process
outgrowth has been found to be regulated by intracellular calcium levels in
differentiating oligodendrocytes (Yoo et al., 1999). Interestingly, in our studies
(Fig. 4.3) intracellular calcium levels remained slightly above control levels after
the initial rise. Such a calcium response is consistent with previously described
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calcium responses mediated by signaling through sodium-dependent glutamate
transporters in astrocytes (Rojas et al., 2007). In the case of astrocytes the initial
rise in intracellular calcium concentrations was found to be amplified by calcium
release from ryanodine sensitive calcium stores (Rojas et al., 2007), which have
also been described to be expressed by cells of oligodendrocyte lineage
(Simpson et al., 1998).
In the major demyelinating disease in human, Multiple Sclerosis (MS), a block
in oligodendrocyte differentiation is considered one of the main causes of
remyelination failure and repair under such pathological conditions (Chang et al.,
2002, Fancy et al., 2010, Kremer et al., 2011). Interestingly, reduced sodiumdependent glutamate transporter protein levels have been reported for white
matter areas surrounding MS lesions (Werner et al., 2001, Pitt et al., 2003). In
addition, retrospective analysis of brain tissue from MS patients revealed
oligodendrocyte differentiation block as the major determinant of remyelination
failure within periplaque white matter regions (Kuhlmann et al., 2008). In light of
our findings that knock-down of sodium-dependent glutamate transporter
expression eliminates the effect of glutamate on the morphological maturation of
differentiating oligodendrocytes (Fig. 4.2F), it is tempting to speculate that
changes in sodium-dependent glutamate transporter expression may contribute
to the differentiation block seen in MS. It is of further note that glutamate levels
have been found elevated in MS brains (Werner et al., 2001, Srinivasan et al.,
2005, Trapp and Stys, 2009). These changes in glutamate homeostasis have
been implicated in mediating excitotoxicity (Pitt et al., 2003, Matute, 2011).

95

However, human oligodendrocytes appear to be largely resistant to such
glutamate-mediated injury (Wosik et al., 2004) and thus changes in glutamate
homeostasis and sodium-dependent glutamate transporter expression may, at
least under certain circumstances, primarily limit repair under pathological
conditions as they are seen in the CNS of MS patients.
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FIGURE 4.1: Sodium-dependent glutamate transporters are expressed in
differentiating oligodendrocytes. A: Bar graph representing sodium-dependent
glutamate transporter mRNA levels as determined by qRT-PCR analysis. Total
glutamate transporter mRNA levels (Glast+Glt-1+Eaac1) were set to 100% and
the values for the individual gene-specific mRNA levels were adjusted
accordingly. Data represent means ± SEM (n = 3 independent experiments,
***p≤0.001, ANOVA). B: Sodium-dependent glutamate transporter protein levels
as determined by immunoblot analysis. Representative blots are shown. The
numbers to the left indicate molecular weights in kDa.
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FIGURE 4.2: The activation of sodium-dependent glutamate transporters
promotes the morphological aspects of oligodendrocyte differentiation. A:
Representative images of differentiating oligodendrocytes immunostained using
O4 hybridoma supernatants and treated as indicated: control (Ctrl), L-glutamate
(Glu; 100 µM), a non-transportable inhibitor of sodium-dependent glutamate
transport (TBOA; 100 µM). Scale bars: 20 µm. B-D: Bar graphs representing
quantitative analyses of network areas (Dennis et al., 2008). Cells were treated
as indicated: control (Ctrl), L-glutamate (Glu, 100 µM), a non-transportable
inhibitor of sodium-dependent glutamate transport (TBOA, 100 µM), D-aspartate
(Asp, 100 µM). The mean values for control (non-treated) cells were set to 100%
and experimental values were calculated accordingly. At least 30 cells per
condition and experiment were analyzed in 3 independent experiments (i.e. a
total of at least 90 cells per condition). Data represent means ± SEM (***p≤0.001
compared to control, ANOVA). E: Bar graph depicting the number of MBPimmuno-positive cells normalized to the number of Hoechst-positive nuclei. The
inset shows a representative image of cells cultured under control (non-treated)
conditions and stained with an antibody specific for MBP (left panel) as well as
with Hoechst to visualize nuclei (right panel). Cells were treated as indicated and
control (non-treated) values were set to 100%. Experimental values were
calculated accordingly. Data represent means ± SEM of 3 independent
experiments in which a field of view of 508 µm2 per coverslip and 3 coverslips per
condition and experiment were analyzed. Three independent experiments were
performed. ANOVA revealed no statistically significant difference (p≤0.05). F: Bar
graph depicting the network area upon siRNA-mediated knock-down of individual
sodium-dependent glutamate transporters (as indicated) and subsequent
treatment with L-glutamate (Glu, 100 µM). The mean value for control cells (siCtrl
non-treated) was set to 100%. Experimental values were calculated accordingly.
At least 30 cells per condition and experiment were analyzed in 3 independent
experiments (i.e. a total of at least 90 cells per condition). Data represent means
± SEM (***p≤0.001 compared to siCtrl non-treated, ANOVA).
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FIGURE 4.3: The activation of sodium-dependent glutamate transporters
increases intracellular calcium levels in differentiating oligodendrocytes. A:
Representative pseudo-colored images of fura-2 AM ratio fluorescence
measurements made in differentiating oligodendrocytes and upon treatment with
D-aspartate (Asp). The bar to the left represents a relative color scale indicating
low (L) and high (H) calcium levels. B-C: Time course of changes in free
intracellular calcium concentrations [Ca2+] as detected by fura-2 AM ratiometric
measurements made in differentiating oligodendrocytes and upon different
treatments as indicated in the inset shown in the upper right in B and C. Start of
treatment is indicated by the arrow. The graphs represent means ± SEM of
measurements taken from 9 cells per treatment group and experiment and from
3 independent experiments (i.e. a total of 27 cells per treatment group).
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FIGURE 4.4: Activation of sodium-dependent glutamate transporters leads to a
transient phosphorylation event at CaMKIIβ’s S371 residue. A: Bar graph
depicting a quantitative analysis of the oligodendrocyte’s network area (Dennis et
al., 2008). Cells were first pre-treated with the pharmacological CaMKII inhibitor
KN-93 or its inactive derivative KN-92 as control and then incubated in the
absence or presence (+Glu) of 100 µM L-glutamate. The mean values for control
cells (pre-treated with KN92 and incubated in the absence of L-glutamate) were
set to 100% and experimental values were calculated accordingly. At least 30
cells per condition and experiment were analyzed in 3 independent experiments
(i.e. a total of at least 90 cells per condition). Data represent means ± SEM
(***p≤0.001 compared to control, ANOVA). The inset (upper right) depicts
representative images of differentiating oligodendrocytes immunostained with O4
antibodies and treated with KN-92 plus L-glutamate (left) or KN-93 plus Lglutamate (right). Scale bars: 5µm. B, inset in H: Representative Western blots
depicting CaMKII phosphorylation (pCaMKIIβ S371, pCaMKII T286/7) or total
CaMKIIβ protein levels. GAPDH protein levels are shown representatively for the
Western blot for which anti- pCaMKII T286/7 (B) or anti-pCaMKIIβ S371 (inset in H)
antibodies were used. C-H: Bar graphs depicting the levels of pCaMKIIβ S371
(C,F-H), total CaMKIIβ (D) or pCaMKII T286/7 (E) at different time-points after
addition of L-glutamate (Glu) (C-F), at time-point 60 min after addition of Lglutamate and prior pre-treatment with or without TBOA (G) or after transfection
with siRNA pools as indicated and L-glutamate treatment for 60 min (H). Levels
of phosphorylated or total CaMKII protein were normalized to GAPDH protein
levels. The mean normalized values for control (non-treated) cells were set to
100% (horizontal line) and experimental values were calculated accordingly.
Data represent means ± SEM of 3 independent experiments (*p≤0.01 compared
to control, ANOVA).
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FIGURE 4.5: Phosphorylation events within CaMKIIβ’s actin binding/stabilizing
domain regulate the association of CaMKIIβ with filamentous F-actin and the
glutamate-mediated promotion of the morphological aspects of oligodendrocyte
maturation. A: Representative images of cells of the oligodendroglial cell line
CIMO nucleofected with plasmids encoding eGFP fusion proteins of CaMKIIβ
(WT and mutant forms as indicated) and stained for F-actin (phalloidin). Scale
bars: 5 µm. B: Representative images of differentiating oligodendrocytes
nucleofected with plasmids encoding eGFP fusion proteins of CaMKIIβ (WT and
mutant forms as indicated). Arrowheads point toward eGFP-CaMKIIβallA localized
at oligodendrocyte growth cones and process branching points. Scale bars: 5
mm. C: Bar graph depicting a quantitative analysis of the oligodendrocyte’s
network area (Dennis et al., 2008). Cells were nucleofected as indicated and
then incubated in the absence or presence (+Glu) of 100 µM L-glutamate. The
mean values for control cells (nucleofected with a eGFP encoding plasmid and
incubated in the absence of L-glutamate) were set to 100% and experimental
values were calculated accordingly. At least 30 cells per condition and
experiment were analyzed in 3 independent experiments (i.e. a total of at least
90 cells per condition). Data represent means ± SEM (***p≤0.001 compared to
control, ANOVA).
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FIGURE 4.6: Proposed model for a glutamate transporter-CaMKIIβ-actin
cytoskeleton axis in the regulation of oligodendrocyte maturation. A: L-glutamate
(Glu) stimulates the activity of sodium-dependent glutamate transporter activity,
which in turn leads to an increase in intracellular sodium (Na+) levels, activation
of the reverse mode of the sodium/calcium exchanger and a transient increase in
intracellular calcium (Ca2+) levels. B: The transient increase in intracellular
calcium levels leads to phosphorylation events within CaMKIIβ’s actin
binding/stabilizing domain (pCaMKIIβS371), detachment of CaMKIIβ from
filamentous F-actin and the opening of a time window during which cytoskeletal
rearrangements and morphological remodeling can occur. C: Upon deactivation
(dephosphorylation) of CaMKIIβ, CaMKIIβ binds to filamentous F-actin and
thereby stabilizes the newly arranged cytoskeleton. Such cycles of activation and
de-activation of CaMKIIβ’s actin binding activity allow re-organization of the actin
cytoskeleton while at the same time preventing its uncontrolled disintegration.
adapted from Okamoto et al, 2009(Okamoto et al., 2009).
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FIGURE 4.S1: siRNA-mediated gene silencing results in a significant knockdown of sodium-dependent glutamate transporter expression in differentiating
oligodendrocytes. A: Bar graph depicting sodium-dependent glutamate
transporter protein levels upon siRNA-mediated gene silencing and normalized to
GAPDH protein levels. The mean value for cells treated with the control siRNA
pool (siCtrl) was set to 100% (horizontal gray line) and experimental values were
calculated accordingly. Data represent means ± SEM of 3 independent
experiments (***p≤0.001,*p≤0.05, ANOVA). B: Representative Western blots
depicting protein levels for GLAST, GLT-1, EAAC1 and GAPDH (as control).
GAPDH protein levels are shown representatively for the Western blot, for which
anti-EAAC1 antibodies were used.
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CHAPTER 5
Final Conclusions

The myelin sheath that is produced by oligodendrocytes in the CNS serves a
unique and critical function for proper conduction of nerve signals. Disruption of
the myelin sheath leads to improper nerve conduction resulting in unpredictable
debilitating afflictions for people as seen in the most well known demyelinating
disease MS. As mentioned in Chapter 1, in the MS brain there are
oligodendrocytes present within CNS-located lesions, however, they lack the
ability to efficiently remyelinate (Chang et al., 2002). When remyelination does
occur, the myelin sheath is thinner and is too inefficient to provide proper axonal
protection and propagation of the electrical signal (Patrikios et al., 2006,
Goldschmidt et al., 2009, Bradl and Lassmann, 2010, Emery, 2010). A better
understanding of the molecular mechanisms that regulate oligodendrocyte
maturation and development is thought to provide molecular and genetic clues to
better understand not only developmental myelination but also how to promote
remyelination under pathological conditions.
Unlocking the molecular secrets to myelination may enlighten researchers to
a complex understanding of the morphological maturation of the oligodendrocyte.
Morphological maturation along with gene regulation can go hand in hand or be
separate, and to an extent one can drive the one or the other (Boggs, 2006,
Boggs et al., 2006, Forrest et al., 2009, Lafrenaye and Fuss, 2010). Myelination
requires the maturation of progenitor cells into cells that extend processes and
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form a complex process network. These premyelinating oligodendrocytes then
transition into mature myelinating oligodendrocytes (Song et al., 2001, Bacon et
al., 2007, Bauer et al., 2009). These large scale morphological changes are
mediated by precisely regulated changes in the actin cytoskeleton (Bauer et al.,
2009). This fine actin regulation is highlighted by myelin defects seen in
knockouts or knockdowns of cytoskeletal regulatory proteins such as WAVE1,
cdc42, RAC1, Integrin-linked kinase (ILK), and Mayven (Jiang et al., 2005, Kim et
al., 2006, Thurnherr et al., 2006, O'Meara et al., 2013). Interestingly, in MS
lesions proteomic studies have revealed a large amount of misregulated
cytoskeletal regulatory mechanisms (Jahn et al., 2009, Satoh et al., 2009).
As stated above, changes in oligodendrocyte development usually are
characterized by large scale changes of the oligodendrocyte process network
and the underlying actin cytoskeleton. In Chapter 2, by using in vitro tissue
culture as well as in vivo knockout and knock-in models, CaMKIIβ has been
shown to be a critical component of the molecular mechanisms regulating
oligodendrocyte maturation and CNS myelination. CaMKIIβ’s properties in
binding and stabilizing actin have been established in neuronal spine morphology
but our finding of CaMKIIβ’s role in the regulation of oligodendrocyte
development and the formation of a complex process network is novel. (Shen et
al., 1998, O'Leary et al., 2006, Okamoto et al., 2007, Lin and Redmond, 2008,
Okamoto et al., 2009, Sanabria et al., 2009).
In neurons and oligodendrocytes, the stabilization along with the
destabilization of the actin cytoskeleton causes the fluidity of process elongation
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along with membrane spreading (Bradke and Dotti, 1999, Okamoto et al., 2007,
Okamoto et al., 2009). Furthermore, in neurons, the bundling and unbundling of
actin acts to alter and stabilize the morphology of dendritic spines based on
activity dependent plasticity (Okamoto et al., 2009). Evidence presented in
Chapter 2 points towards the binding of actin to CaMKIIβ using colocalization
studies. The evidence also suggests that once CaMKIIβ’s catalytic activity and
actin binding is inhibited with a pharmacological inhibitor, there is no indication of
colocalization (Chapter 2). Actin colocalization with CaMKIIβ suggests that the
model of CaMKIIβ binding and dissociating from actin allows stabilization and
alteration of the cytoskeleton respectively. Although this was developed for
remodeling of the dendritic spine, it could also apply to the remodeling of
oligodendrocyte protrusions. Based on previous data, one could assume that
process outgrowth and maintenance of the process cytoskeleton is dependent on
the balanced destabilization (unbinding) and stabilization (binding) of the actin
cytoskeleton to a bundling molecule such as CaMKIIβ for controlled process
outgrowth and myelination (Bradke and Dotti, 1999, Sparrow et al., 2012).
Similarly, the activation and then deactivation of cofilin (the actin filament
severing and depolymerizing factor) regulates Schwann cell myelination
(Sparrow et al., 2012). This provides further support that well-balanced and
controlled cytoskeletal reorganization and fluidity are critical for proper
myelination.
In the CaMKIIβ knockout mice, differences in myelin thickness in the ventral
spinal cord were noticed in young and adult mice indicating that CaMKIIβ is
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critical for proper myelination of the CNS. A similar phenotype has been seen in
in conditional (oligodendrocyte specific) ERK1/ERK2 double knockout mice.
Thinner myelin was seen with no changes in the numbers of oligodendrocytes;
however, there were some changes seen in the expression of myelin genes (Ishii
et al., 2012). The resulting similar phenotype seen between CaMKIIβ knockouts
and ERK1/ERK2 double knockouts could potentially be attributed to overlapping
signaling mechanisms. Once upstream signals (ERK1/ERK2 or CaMKIIβ) are
knocked out, similar phenotypes arise. Conversely, these two signaling pathways
could be different but provide a similar function since myelination is critical for
normal development of the CNS. If we assume that CaMKIIβ is binding to actin
and regulates actin binding and unbinding during the unbound state, it could
potentially modulate ERK1/2 signaling as it has been described to do in other cell
types (Lu et al., 2005). Additionally, ERK1/2 signaling in other cell types is linked
to signaling that regulates actin polymerization and substrate detachment of the
actin cytoskeleton when ERK1/2 signals to myosin light chain kinase or Calpain
respectively (Katz et al., 2007). Therefore signaling mechanisms that regulate
ERK1/2 dependent myelination could potently overlap with signaling related to
CaMKIIβ dependent myelination. Changes in gene expression cannot be
compared specifically between ERK1/2 knockouts and CaMKIIβ knockouts
because gene expression has not been carefully assessed in the latter. However,
by comparing studies done in vitro by knocking down CaMKIIβ with studies that
knocked out ERK1/2, it could be assumed that these signaling mechanisms
could be different but provide a similar outcome. In this proposed outcome,
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ERK1/2 is regulating the genetic component of oligodendrocyte development and
CaMKIIβ is regulating the morphological maturation component of
oligodendrocyte development (Ishii et al., 2012, Waggener et al., 2013). Thus,
two different developmental pathways are impacted but the same improper
regulation of myelination could potentially be observed.

Glutamate activates CaMKIIβ and increases the overall morphology of the
oligodendrocyte’s process network
As mentioned in Chapter 3, glutamate signaling in the brain is critical for
normal brain development. Furthermore, as the nervous system develops and
oligodendrocyte processes are looking to attach to axons, glutamate is being
released in a vesicular fashion from unmyelinated axons (Kukley et al., 2007,
Ziskin et al., 2007, Hamilton et al., 2010). The data presented in Chapter 4
suggest that maturing oligodendrocytes may respond to axonal released
glutamate which would stimulate myelination.
In Chapter 4, the data demonstrated that sodium-dependent glutamate
transporters are important for the regulation of oligodendrocyte differentiation.
More specifically, the data showed that activation of sodium-dependent
glutamate transporters promotes oligodendrocyte morphological maturation via
transient increases in intracellular calcium and phosphorylation of CaMKIIβ’s S371
site found within CaMKIIβ’s actin binding/stabilization domain. These
phosphorylation events seem to mediate CaMKIIβ’s association with F-actin and
give further insight into the role that CaMKIIβ potentially plays during actin
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binding and stabilization of the oligodendrocyte process network. These data
show that there is a functional relationship between glutamate transporters and
oligodendrocyte development. It has been shown that electrical activity via axons
regulates myelination (Malone et al., 2013). More specifically, the glutamate
released from electrically active unmyelinated axons has been implicated in
increased development and then subsequent myelination of oligodendrocyte
progenitor cells (Kukley et al., 2007, Ziskin et al., 2007, Bakiri et al., 2009,
Kolodziejczyk et al., 2010).
Altering the binding properties of the serine/threonine residues within the
actin binding domain changes the way CaMKIIβ binds to actin. This
phosphorylation-dependent binding of actin is a novel finding and our data
suggests the regulatory mechanisms mediated by CaMKIIβ’s actin binding site in
oligodendrocytes are comparable to ones proposed in neurons and in particular
in dendritic spines (Okamoto et al., 2009). These data are the first evidence that
oligodendrocytes use CaMKIIβ to bind to actin and that the phosphorylation of
serine/threonine residues within the actin binding site regulate the arrangement
and organization of the oligodendrocyte actin cytoskeleton.
If CaMKIIβ is critical for proper myelination, then alterations may be seen
in diseases such as MS that have oligodendrocytes with simple process
morphologies and limited/insufficient myelination. In some MS lesions, there
seems to be an upregulation at the S371 site of CaMKIIβ (our own unpublished
data).
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Interestingly, the signaling mechanisms that potentially govern
oligodendrocyte process guidance towards the axon may indeed be altered in
MS. Higher levels of glutamate have been shown in normal appearing white
matter and lesioned areas of MS brains (Werner et al., 2001, Trapp and Stys,
2009, Tisell et al., 2013). However, lower levels of glutamate transporter
expression have also been reported for MS lesions (Werner et al., 2001, Pitt et
al., 2003). Since our data show that glutamate stimulates the phosphorylation of
the actin biding domain of CaMKIIβ and causes it to dissociate from F-actin,
physiological higher concentrations of glutamate or more glutamate/Ca2+ being
transported could cause destabilization of the actin cytoskeleton. This effect
would be similar to the CaMKIIβAllD (always actin unbound) mutant, expression of
which results in a significant decrease in the process network of
oligodendrocytes. If the environment around these immature oligodendrocytes is
altered (higher glutamate concentrations), then constant destabilization of the
actin cytoskeleton could lead to process retraction or process collapsing (Meng
et al., 2010, Nagel et al., 2012). It is critical that the periods of actin
destabilization be followed up with periods of actin stabilization to achieve a
proper balance of actin dynamics (Sparrow et al., 2012).
Downstream activation of the reverse mode of NCX3 (sodium calcium
exchanger) is one way to restore the Na+ equilibrium after glutamate transport.
As previously discussed, the restoration of Na+ efflux allows for Ca2+ influx, at
least in Bergmann glia cells (Martinez-Lozada et al., 2011). The subcellular
location of NCX3 was described to be within the process network of MOG
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positive cells in culture and also within compacted myelin in MBP positive cross
sections of axons in spinal cord white matter (Boscia et al., 2012b). It has been
theorized and speculated but poorly understood for years that there are signals
that are exchanged between the axon and the myelin sheath to communicate the
regulation of thickness and maintenance of the myelin sheath (Nave and Trapp,
2008, Nave, 2010). This has been well demonstrated for the PNS but based on
current research, the signals that control these events are more complex in the
CNS (Nave and Salzer, 2006, Brinkmann et al., 2008, Taveggia et al., 2008). The
CNS most likely requires additional uncharacterized signals to govern the
regulation of myelin thickness. The mechanisms of glutamate signaling in
oligodendrocytes regulating the cytoskeleton via CaMKIIβ could provide insight
into this area of uncertainty.
This dissertation focuses on the role that CaMKIIβ plays on oligodendrocyte
process network formation and myelination with regards to an association of
CaMKIIβ with the actin cytoskeleton. What has not been mentioned or
investigated is the multifunctional kinase role that CaMKIIβ or any of the
expressed Camk2 genes can play in oligodendrocyte development. The neuronal
model proposes that a catalytically active CaMKIIβ disassociates from actin and
performs its traditional and well known role as a multifunctional kinase (Okamoto
et al., 2007, Lin and Redmond, 2009, Lakhanpal et al., 2011). In relation to
CaMKIIβ’s kinase role, it has been shown that CaMKIIβ is a regulator of LIMK1
by phosphorylation of LIMK1 Thr-508 site, which is then responsible for
phosphorylation of the actin severing/depolymerizing factor cofilin (Saito et al.,
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2013). LIMK1 has been implicated in Schwann cells to activate cofilin and to thus
be essential for PNS myelination (Sparrow et al., 2012). During the active
unbound state of CaMKIIβ, the phosphorylative effects of the kinase could be
acting to aid in activating actin regulatory proteins such as cofilin via LIMK1.
The data presented in this dissertation give new insights into new molecular
players responsible for morphological changes in the oligodendrocyte process
network. A greater understanding of the molecular mechanisms that underlie
process maturation could provide key clues and potential therapeutic targets for
treating and repairing MS lesions. Oligodendrocyte progenitor cells that are found
in the lesions of MS patients fight a host of mechanisms that keep them from the
proper remyelination for which they are intrinsically designed. Researchers in the
field still question whether immature oligodendrocytes in MS lesions have the
ability to remyelinate. One of the current theories on this topic is that the addition
of a new population of stem cells in the lesion could increase the ability of these
new stem cells to remyelinate (Lindvall and Kokaia, 2006, Zawadzka et al.,
2010). The second theory in the field is that the cells are intrinsically normal but
the local environment is unable to support remyelination (Ruckh et al., 2012,
Stoffels et al., 2013). In recent studies, it was shown that when adding a younger
environment via new young macrophages and blood derived factors, the
inhibitory environment was rejuvenated and allowed for proper remyelination of
older oligodendrocyte progenitor cells (Ruckh et al., 2012). One of the reasons
that remyelination could be occurring is that macrophages which are not normally
expressed in the CNS can take up glutamate via the EAAT transporter system
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(Rimaniol et al., 2000). This removal of higher levels of glutamate from the
surrounding cells could restore the proper influx of glutamate, which would
restore the balance of Ca2+ influx into the cells. This reduction or controlled
elevation in Ca2+ levels would allow CaMKIIβ to normally move from an actin
bound and unbound state with restored balance of destabilization to stabilization
of actin.
This dissertation and the research presented here gives overwhelming
support for the role that CaMKIIβ plays in the regulation of actin with regards to
oligodendrocyte process morphology and myelination. Unveiling novel signaling
mechanisms into the complex and poorly understood field of myelination pushes
researchers closer to a better understanding of this principle. These findings are
of great significance because there are no current therapies available for MS
patients today that address the issue of remyelination. This research and other
research into oligodendrocyte development are leading to a better understanding
of the molecular mechanisms that promote oligodendrocyte differentiation during
development that have the potential to reveal novel targets for designing
remyelinating therapies.
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CHAPTER 6
Supplementary Unpublished Data and Protocols

CaMKII Activity In Oligodendrocytes
CaMKII activity was measured in primary cells from P4 rat pups that were
imunopanned with O4. Once immunopanned cells were either process right away
or plated on glass coverslips coated with .1ug/ul of fibronectin and then
harvested after a day. Cells were collected and rinsed centrifugally (2000×g for

5 min) with ice-cold PBS (phosphate-buffered saline) containing 2.5 mM
EGTA. Cellular pellets were resuspended in 3 volumes of ice-cold
homogenization buffer, which consisted of 20 mM Hepes (pH 7.4), 2.6 mM
EGTA, 20 mM MgCl2, 80 mM β-glycerol phosphate, 5 mM NaF, 0.1 µM
okadaic acid (GIBCO-BRL), 0.1 µM calyculin A (GIBCO-BRL), 0.1 mM
dithiothreitol, 0.01 mg/ml each chymostatin, leupeptin, aprotinin, pepstatin
and soybean trypsin inhibitor (Sigma, St. Louis, MO). Samples were then
sonicated (two 5-s bursts on ice), centrifuged at 12 000×g for 15 min at
4°C and either assayed immediately or frozen and stored at −80°C
(Tombes et al., 1999).
For figure 6.1 P4 O4 immunopanned cells were harvested for CaMKII
activity assay immediately after immunopanning. Cells from DRG
cocultures were harvested after DRG explants were incubated for 1 week
post explant. ATX and lacZ was added at 0.1µg/ml for 1 hour incubated at
37°C.
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Figure 6.1: Premyelinating postmigratory oligodendrocytes express functional
CaMKII. P4 O4 imunopanned rat oligodendrocytes express functional CaMKII.
However, oligodendrocytes CaMKII activity is half of dorsal root ganglia neurons
(DRG). However when DRGR cells cultures are incubated with ATX 0.1µg/ml or
control LacZ 0.1µg/ml for 1 hour at 37°C before cells were harvested for activity
assay (Tombes et al., 1999). oligodendrocytes N=2 DRG N=1.
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Figure 6.2: Premyelinating postmigratory oligodendrocytes express functional
CaMKII that responds to stimulation with autotaxin and T3. P4 O4 panned
oligodendrocytes were plated on 0.1µg/µl fibronectin coated coverslips. (A) Cells
were incubated for 1 day and then stimulated with either 0.1µg/µl autotaxin or
control LacZ for 1 hour at 37°C before harvesting for CaMKII activity assay. Cells
stimulated with ATX had greater kinase activity when compared to LacZ
stimulated cells. N=2 (B) Oligodendrocytes treated with differentiation media
containing N2T3 had higher kinase activity compared to cells treated with
mitogens PDGF/FGF N=2
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Inhibition of CaMKII alters MBP expression in zebra fish
Treating fish with 10µM KN-93 for 24 hours alters the expression of MBP mRNA
in the hind brain but not the posterior lateral line of 72 hour zebra fish. Fish
treated in 35mm dish with a final concentration of 10µM KN-93, KN-92 or DMSO.
Ran institu hybridization for MBP to detect altered MBP expression.
Protocol for insitu hybridization

Zebrafish Whole Mount In Situ Hybridization
(NBT/BCIP detection)
________________________________________________________________
____________
General embryo preparation:
Stage embryos to desired age, anesthetize with MESAB (minimum 42ul/ml) and
fix with 4% PFA in 1X PBS (new, never thawed)
O/N at +4C
Wash embryos with 1x PBT 5min (x2)
Quick wash embryos with 100% MeOH, then change to fresh 100% MeOH.
Embryos can be stored in Methanol long term at -20C
(If need to use embryos sooner, put in 100% MeOH at RT for 15min, then
transfer to -20C for 2 hrs)
Day 1 - All steps during day 1 should be RNase-free (using DEPC water) and are
carried out at RT except when noted
Rehydrate embryos through methanol/PBT series - discard in MeOH waste!
66/33, 33/66, 0/100: 10’ each wash shaking -1mL
Wash with PBT 5min (x2) – 1mL
Treat with proteinase K if older than 24hpf (do not freeze/thaw stock more than
5x)
5µg/ml in PBT at 37C: 0.5min per hour age (ex. 30min for 60hpf) - 500uL
Treat with ice-cold acetone 8min at -20C (or on ice) – 500µL
Wash 1X PBT 5min x2 – 1mL
Post-fix with 4% PFA in 1xPBS 20min – 500µL (discard in PFA waste!)
Wash with PBT 5min x5 -1mL
Incubate embryos in pre-warmed 1xHyb- at 65C 5min – 500µL - discard all Hyb
mixes in formamide waste!
Remove 1XHyb- and prehybridize in prewarmed 1xHyb+ for at least 1hr at 65C –
500uL
Dilute probe stocks: 1:100-1:300 in 1xHyb+ (if first time using)
**Note: is some cases, it is best to prehybridize a newly diluted probe with
embryos for one night before doing the in situ, this can lower background
Preheat probe to 65C
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Aspirate prehybridization solution and replace with pre-warmed probe: 65C ~18
hr (minimum 50-100uL probe per tube – make sure all embryos are suspended)
Day 2
Prewarm solutions below at 65C before using
Remove diluted probe/hybridization solution and SAVE for re-use (use 200µL
pipette tip) be sure to change tips when using different probes!
Washes (500µL per tube) - use drawn out Pasteur pipette or 1mL pipette to
aspirate
Use 1mL volumes for all washes - Discard all solutions with Hyb mix in separate
formamide waste!
1xHyb- (quick wash) (x1)
66% Hyb-/33% 2xSSC 10’ 65C (x1)
33% Hyb-/66% 2xSSC 10’ 65C (x1)
2xSSC 10’ 65C (x1)
0.2xSSC 20’ 65C (x2)
66% 0.2xSSC/33% 1xPBT 5’ RT (x1)
33% 0.2xSSC/66% 1xPBT 5’ RT (x1)
1xPBT 5’ RT (x1)
Block: Roche western blocking reagent 1:10 in 1XPBT for at least 1hr at RT on
shaker – 500µL
Dilute antibodies in blocking buffer: (500µL per tube)
Note: do NOT use antibodies after they have expired!!!
Anti-Dig-AP 1:10,000
Anti-Fluorescein-AP 1:10,000
Incubate in primary antibody O/N at 4C (lay tubes on side)
Day 3
Washes (all 1mL volume and on shaker)
1xPBT (quick wash) (x1)
1xPBT 15’ RT (x6)
1x coloration buffer + 0.1% Tween-20 5’ RT (x3)
Coloration reaction: 1x coloration buffer + 0.1% Tween-20 + NBT/BCIP
(4.5µL/3.5µL per 1mL of coloration buffer), let develop in dark and monitor signal,
put at 4C or RT in eppendorf tubes for indicated times:
ATX-dig
MBP-dig
DM20-dig
Olig1-dig

2 nights at 4C
1 night at 4C
1.5hrs at RT
1 night at 4C

Fli1-dig
~2hrs at RT
Foxa2-dig
1 night at 4C
Foxa2-fl
1 night at 4C
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Olig2-dig
Sox10-dig

1 night at 4C
1 night at 4C+couple hrs @ RT

Note for NBT/BCIP: When solution gets older, it may precipitate out so heat to
37C for a few minutes to put back into solution
If first time using probe: Monitor color reaction under dissection scope
frequently!
When coloration reaction completed:
Aspirate coloration solution
Quick was embryos with 1xPBT
Dehydrate in methanol to clear out background for a few minutes then
store in fresh
methanol at -20C O/N up to a couple of months or minimum
2hrs at RT
Note: fish may look slightly pink but this will disappear after addition of Methanol
Rehydrate through methanol/PBT series then equilibrate in 90% glycerol/PBS for
imaging
Store at +4C
Imaging
Glue coverslips to both sides of a slide to create a space in between; mount fish
in the space using 90% glycerol. Move fish to desired position then place a long
coverslip across the glued coverslips on each side. Nailpolish the long coverslip
to keep in place; slides can be stored at +4C temporarily
Imaging fish from the side: mount fish using 2-3 coverslips on each side of slide;
do not remove the yolk sacs. 3 coverslips works best for 36-48hpf fish; 2
coverslips works well for 60-72hpf fish
Imaging fish dorsally: remove yolk and mount fish with 2 coverslips on each side
Fish can be imaged on Zeiss dissecting microscope in microscopy core using
extended focus software
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Solutions:
PBT: 1X PBS + 0.1% Tween-20
Hyb mix (store at -20C)
Formamide
20x SSC
Heparin, 25 mg/ml
box)
tRNA, 10mg/ml
box)
tween-20, 20%
citric acid, 1M
nuclease-free dH2O

Hyb+
25 ml
12.5ml
0.1ml

Hyb25 ml
12.5ml
-

(+4C)
(RT)
(-20C In situ hyb reagent

2.5ml

-

(-20C In situ hyb reagent

0.25ml
0.46ml
9.19ml
50ml

0.25ml
0.46ml
11.79ml
50ml

(RT)
(RT)
(RT)

Coloration buffer (store at RT)
Tris-HCL, pH 9.5, 1M
MgCl2, 1M
NaCl, 5M
H2O

5ml
2.5 ml
1ml
41.5ml
50ml
-Add Tween-20 immediately before use:
Tween-20, 20% 5µl/ml
NBT stock: 50mg NBT + 0.7ml dimethyl formamide anhydre (71.4mg/mL) store at -20C protected from light
BCIP stock: 50mg BCIP + 1.0ml dimethyl formamide anhydre (50mg/mL) store at -20C protected from light
Reagents needed:
Methanol

Yeast RNA (Applied Biosystems/Ambion

#AM7118)
PBT

20X SSC (American Bioanalytical

#AB1315601000)
Proteinase K (Invitrogen #25530015)

Formamide (Fisher #BP227-500)

4% PFA in PBS

Heparin (Fisher #AC41121-0010)

Acetone

RNase-free dH2O

Tween-20

1M Citric acid

Roche western blocking reagent (Roche#11 921 673 001)

1M Tris-HCl, pH 9.5

Anti-Dig-AP (Roche#11 093 274 910)

1M MgCl2

Anti-Fluorescein-AP (Roche# 1 426 338)

5M NaCl

NBT (Roche: 11 087 479 001)

50% Glycerol/ 1X PBS

BCIP (Roche: 10 760 994 001)
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Figure 6.3: Inhibition of CaMKII by KN-93 alters the expression of mbp mRNA.
(A) Fish treated with 10µM of the CaMKII inhibitor KN-93, the control KN-92, or
vehicle control DMSO for 24hrs. Fish when treated with KN-93 showed a
significant decreased or absent mbp mRNA expression compared to the two
controls. However, in treatment groups and control groups the PNS structure of
the posterior lateral line was not effected. (B) Statistical and graphical
representation of the different binned categories of expression of mbp. In KN-93
treated fish absent or diminished mbp expression accounted for almost 90%
(when taken together) of the fish seen in these groups. In the control groups, only
5% had an absent or diminished phenotype.
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Inhibition of CaMKII alters in vivo morphology of oligodendrocytes in the
zebrafish spinal cord.
Nkx2.2a: meGFP fish were treated with 10µM KN-93 or the control KN-92 for 24
hours. Fish were then fixed with 4% PFA in 1X PBS (new, never thawed) O/N at
+4C. Washed embryos with 1x PBT 5min (x2). Mounted on slides with coverslip
spacers and imaged on a Zeiss 510 multiphoton microscope with a 40x objective
and niquist sampling.
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Figure 6.4: Inhibition of CaMKII alters the morphology to a much simpler
morphology of oligodendrocytes in the zebrafish spinal chord. Fish treated for
24hrs with KN-93 or the control KN-92 were imaged at 72hpf. A distinct
difference was noticed in the simplistic morphology in the KN-93 treated fish vs.
the KN-92 fish. A li phenotype with thicker process (indicating myelin) was seen
in the control vs. the treatment group with more immature looking cells that have
a highly branched morphology but not myelinating.
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Colocalization of DM20 positive cells with Camk2b1 in zebrafish ventral
spinal cord.
In situ hybridization on 72hpf zebrafish with dm20 probe and Camk2b1 probe.
Insitu hybridization was performed then cryostat sectioning of fish embedded In
OCT after cryoprotection was performed (20% sucrose ) were cut at 20µM and
mounded on slides and imaged on Leica confocal microscope.
Methods for double insitu hybridization.
Zebrafish Whole Mount Double Fluorescent in situ Hybridization
________________________________________________________________
____________________
Adapted from Julich et. al., 2005; Clay and Ramakrishnan, 2005;
Brend and Holley, 2009; Jim Lister and Bruce Appel (3/14/06) lab protocols
Update 6/8/10
General embryo preparation:
Stage embryos to desired age, anesthetize with MESAB (minimum 100ul/ml) and
fix with 4% PFA in 1X PBS (new, never thawed) O/N at +4C
Wash embryos with 1x PBT 5min (x2)
Quick wash embryos with 100% MeOH, then change to fresh 100% MeOH.
Embryos can be stored in Methanol long term at -20C
(If need to use embryos sooner, put in 100% MeOH at RT for 15min, then
transfer to -20C for 2 hrs)
Probes: Use both a Dig- and fluorescein-labeled probe; look at notes to decided
which to use
Day 1 - All steps during day 1 should be RNase-free (using DEPC water) and are
carried out at RT except when noted
Rehydrate embryos through methanol/PBT series
66/33, 33/66, 0/100: 10’ each wash shaking (1mL)
Pre-treat embryos with 1% H2O2 in PBT 30min to inactivate endogeneous
peroxidase activity (500µL)
Fix in 4% PFA 20min – 500µL (discard in PFA waste!)
Wash with PBT 5min (x2) – 1mL
Treat with proteinase K if older than 24hpf (do not freeze/thaw stock more than
5x) (500µL)
10µg/mL in PBT at RT: 30min (for 36hpf to 5dpf); 10min (18-somite to
24hpf)
Treat with ice-cold acetone 8min at -20C (or on ice) - 500µL
Wash 1X PBT 5min x2
Post-fix with 4% PFA in 1xPBS 20min – 500µL (discard in PFA waste!)
Wash with PBT 5min x5 -1mL
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Incubate embryos in pre-warmed 1xHyb- at 65C 5min – 500µL - discard all Hyb
mixes in formamide waste!
Remove 1XHyb- and prehybridize in prewarmed 1xHyb+ for at least 1hr at 65C –
500uL
Dilute probe stocks: 1:100-1:300 in 1xHyb+ (if first time using)
**Note: is some cases, it is best to prehybridize a newly diluted probe with
embryos for one night before doing the in situ, this can lower background
Preheat probe to 65C
Aspirate prehybridization solution and replace with both pre-warmed probes
together: 65C ~18hr (minimum 50-100µL probe per tube – make sure all
embryos are suspended) also run single in situs on your experimental gene (see
“controls” section at end of protocol)
For negative controls for fluorescence do not add probes
Day 2
Prewarm solutions below at 65C before using
Remove diluted probe/hybridization solution and SAVE for re-use (use 200µL
pipette tip) be sure to change tips when using different probes!
Washes (500µL per tube) - use drawn out Pasteur pipette or 1ml pipette to
aspirate
**Note: Discard all solutions with Hyb mix in formamide waste
1xHyb- (quick wash) (x1)
66% Hyb-/33% 2xSSC 10’ 65C (x1)
33% Hyb-/66% 2xSSC 10’ 65C (x1)
2xSSC 10’ 65C (x1)
0.2xSSC 20’ 65C (x2)
66% 0.2xSSC/33% 1xPBT 5’ RT (x1)
33% 0.2xSSC/66% 1xPBT 5’ RT (x1)
1xPBT 5’ RT (x1)
Block: Roche western blocking reagent 1:10 in 1XPBT for at least 1hr at RT on
shaker – 500µL
(note: antibodies should be preincubated for an hour before use – read below*)
Antibodies: Optimize which order the antibodies should be added for your
probes – look at “notes” section below to optimize
Dilute antibodies in blocking buffer (500µL)
Anti-Dig-POD (HRP) 1:1000
Anti-Fluorescein-POD (HRP) 1:500
*Preincubate diluted antibodies in blocking buffer for at least 1hr before adding to
embryos
Incubate in antibody O/N at 4C (lay tubes on side and make sure all embryos are
submerged)
Day 3 (after TSA amplification all steps must be carried out in the dark)
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Wash: 1xPBT (quick wash) (x1) - 1mL
Wash: 1X PBT 15min (x6) – 1mL
Prepare TSA/Cy3 or TSA/Fluorescein solution 1:50 in amplification reagent (spin
down TSA substrate before using: 10,000rpm for 1min) and add to embryos for
30-60min at RT (may need to optimize time for each probe)
Try to use the least amount of volume possible! ~50µL per tube depending on
how many embryos have; lay tubes on side, shake gently on orbital shaker and
protect from light from this step on!!
Wash: 1X PBT 15min (x6) – 1mL
Block peroxidase activity of first antibody with 1% H2O2 in PBT 30min at RT 500µL
Wash: 1X PBT 10min (x3) - 1mL
Block for second antibody: Roche western blocking reagent 1:10 in 1XPBT for at
least 1hr at RT shaking - 500µL
Preincubate antibodies in blocking buffer for at least 1hr before adding to
embryos:
Anti-Dig-POD (HRP) 1:1000
Anti-Fluorescein-POD (HRP) 1:500
Incubate in antibody O/N at 4C (lay tubes on side and make sure all embryos
submerged)
Day 4
Wash: 1xPBT (quick wash) (x1)
Wash: 1X PBT 15min (x6)
Prepare TSA/Cy3 or TSA/Fluorescein solution 1:50 in amplification reagent (spin
down TSA substrate before using: 10,000rpm for 1min) and add to embryos for
30-60min at RT (may need to optimize time for each probe)
Try to use the least amount of volume possible! ~50µL per tube depending on
how many embryos have; Lay tubes on side, shake gently on orbital shaker
Wash: 1X PBT 15min (x6) – still protect from light!
Nuclear stain (2 options)
1. (TO-PRO-3 iodide 642/661) (protect embryos from light at all steps)
Notes: Fish get very sticky during this stain so be very careful to not get them
stuck into the pipette tip!!
Wash embryos with 2xSSC 5min (x2) at RT 500µL
Incubate in RNase 100µg/mL in 2x SSC (+0.1% Tween-20) for 30min at 37C
(50µL per tube)
(Stock solution of RNaseA is 10mg/mL)
Wash with 2X SSC 3min (x6) at RT - 500µL
Add TO-PRO-3 at 33µg/mL in 2x SSC for 20-30min at RT (50µL per tube)
(Stock solution is 671.42µg/mL)
Wash 2X SSC 3min (x6) - 500µL
Fix with 4% PFA 20min at RT - 500µL
Wash with PBT 5min (x2) – 1mL
137

2. Hoecsht (BisBenzimide H 33258) UV 346/460nm (intercalates A-T regions of
DNA)
Incubate with Hoechst 33258 (1µg/mL) in ddH2O 10min at RT
Wash with 1X PBS 5min (x2)
Wash with ddH2O 5min (x1)
Clear O/N in 90% glycerol/PBS at -20C (it is easier to deyolk fish after the
embryos have cleared O/N)
Imaging
Glue coverslips to both sides of a slide to create a space in between; mount fish
in the space using Vectashield. Move fish to desired position then place a long
coverslip across the glued coverslips on each side. Nailpolish the long coverslip
to keep in place; slides can be stored at -20C temporarily
Imaging fish from the side: mount fish using 2 coverslips on each side of slide;
the yolk sacs do
not have to be removed. Can be imaged using lower
objectives (10x and 20x)
Imaging fish dorsally: remove yolk and mount fish with 1 coverslip on each side
(for higher objectives (40x and 63x) or can use 2 coverslips for lower objectives
(10x and 20x)
Note: fish mounted with 1 coverslip on each side can be imaged using all
objectives. Fish mounted using 2 coverslips cannot be imaged on higher
objectives because the objective pushes on the top coverslip and moves the fish
Note: yolk can cause background fluorescence
If cutting fish with cryostat:
Fix with 4% PFA 20min, wash with PBT 5min (x5)
Soak embryos in 30% sucrose (in 1X PBS) at +4C until they sink and then
leave an extra day or
2 (~1 week total) – protect from light!
Transfer fish to cryomold and fill with O.C.T. (be sure to remove majority
of sucrose)
Transfer block to -80C to freeze and store in sealed bag at -80C

CONTROLS – (must run these controls to make sure there is no unspecific
overlap and that the antibodies are not binding unspecifically)
1.
Single fluorescent in situs of both probes
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2.
Negative control: do not add probes and continue with the protocol
3.
Double fluorescent in situs without adding second antibody on day 3
(leave in block solution
O/N) and continue with TSA amplification: testing
whether H202 is blocking HRP activity of first antibody. If it is not then you will
see both green and red fluorescence (I have tested this and the H2O2 has
always quenched the first HRP!)
NOTES:
(From Brend and Holley, 2009)
§ Fluorescein-labeled probes are weaker than dig-labeled probes, best to
detect the fluorescein-labeled probe first
§ If one of the genes is expressed at a low level, make a dig-labeled probe
for the weak gene and detect it first
§ TSA/Fluorescein should only be used with fluorescein-labeled probe, NOT
dig-labeled probe! (use TSA/Cy3 for dig-labeled probe)
§ Perkin Elmer TSA vs. Invitrogen Alexa TSA kits: Most protocols use the
Perkin Elmer kits, but if decide to use the Alexa-Tyramides, the buffer
supplied does not work; they work only with the Perkin Elmer amplification
diluent
(From Clay and Ramakrishnan, 2005)
§ Roche western blocking reagent consists of 10% casein protein in maleic
acid buffer
Sometimes can detect fluorescent background signal in the neuromasts and
along the fin (Roche western blocking reagent minimizes the majority of the
background but can still see sometimes). I have seen this with the ATX in situs
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Solutions:
PBT: 1X PBS + 0.1% Tween-20
Hyb mix (store at -20C)
Formamide
20x SSC
Heparin, 25 mg/ml
reagent box)
tRNA, 10mg/ml
reagent box)
tween-20, 20%
citric acid, 1M
nuclease-free dH2O

Hyb+
25 ml
12.5ml
0.1ml

Hyb25 ml
12.5ml
-

(+4C)
(RT)
(-20C In situ hyb

2.5ml

-

(-20C In situ hyb

0.25ml
0.46ml
9.19ml
50ml

0.25ml
0.46ml
11.79ml
50ml

(RT)
(RT)
(RT)

Reagents needed:
Methanol

Yeast RNA (Applied Biosystems/Ambion

#AM7118)
PBT

20X SSC (American Bioanalytical

#AB1315601000)
Proteinase K (Invitrogen #25530015)
4% PFA

Formamide (Fisher #BP227-500)

in 1X PBS

Heparin (Fisher #AC41121-

0010)
Acetone

RNase-free dH2O (DEPC)

H2O2

1M Citric acid (Fisher #A940-500)

Tween-20

90% Glycerol/ 1X PBS

Roche western blocking reagent (Roche#11 921 673 001)
Anti-Dig-POD (HRP) (Roche#11 207 733 901)

O.C.T.

Anti-Fluorescein-POD (HRP) (Roche#1 426 346)
TSA Plus Fluorescein system (Perkin Elmer #NEL741001KT)
TSA Plus Cyanine 3 system (Perkin Elmer #NEL744001KT)
TO-PRO-3 iodide 642/661 (Invitorgen #T3605)
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Hoechst SAFC #B2883

Figure 6.5: Double florescent Insitu hybridization of dm20 and camk2b1 mRNA.
dm20 positive (green) cells are labeled in the ventral spinal cord of zebrafish
along with the colocalized camk2b1 (red). First conformation that oligodendrocyte
cells in the fish express camk2b. Bar. 10µm
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Colocalization of active pCaMKII and O4 at the oligodendrocyte cell
surface.
Cells immunopanned from P3 rat pups and plated on fibronectin coated
coverslips (0.1µg/µl) were fixed with 4% paraformaldehyde and blocked with
DMEM 065 containing 10%FCS for 30 min. O4 was placed 1:1 with
DMEM06510%FCS overnight at 4 degrees. Cells were then washed with PBS
and Anti mouse igµ Alexa 594 was used to stain at 1:250 for 1hr at room
temperature. Cells were washed with PBS and then probed with anit pCaMKII
(upstate) 1:100 overnight at 4 degrees. Next day cells were washed with PBS
and stained with alexa 488 anti rabbit at 1:250 for 1 hour at room temperature.
Cells were washed with PBS and then mounted with vectashield on glass slides.
Cells were imaged with the Zeiss 510 mutiphoton microscope
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Figure 6.6: Positive active pCaMKII (green) immunestaining of O4 (red) positive
OLG. Colocalization of active pCaMKII at the membrane surface along with the
surface marker for premyelinating postmigratory oligodendrocytes. Scale bar:
20µM.
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Inhibition of CaMKII alters the expression of oligodendrocyte myelin
markers but not early transcription factors.
P3 A2B5 immunopanned oligodendrocytes were plated on 6 well plates 1million
cells per well and treated with KN-93 or MyrAIP for 6 hours. KN-92 and a Control
Myr Peptied were used as controls. Cell were allowed to sit for 24 hours and then
treated for 6 hours at 10µm for each treatment. Once treatment of KN-93 or
MyrAIP was over, cells were harvested for RNA using the qiagen MINI kit. RNA
was measured and then DNAsed using the ambion turbo DNAse kit. cDNA was
made from the treated RNA using omniscript. With the use of random hexomers.
qRTPCR was performed on cDNA refer to protocol for quantitative approach and
materials.
Generate cDNA using Omniscript Reverse Transcription Kit (Qiagen)
_____________________________________________________________________________
_____________
(For use with 50ng to 2µg RNA)
-In separate PCR size tubes add RNA and RNase-free water to a total volume of 13µL.
-Heat 65C for 5 min in thermocycler then place on ice immediately!
-Make master mix: (recipe is for one reaction, multiply by number of samples running + 10%
extra)
All components come with kit except RNase inhibitor and OligodT:
-RNase inhibitor – be sure to dilute to 10units/µL in Rnase-free dH2O (if comes at different
concentration)
-OligodT (Roche) comes as 40µg (8nmol) solid. The stock is diluted in 80µL Rnase-free dH2O to
100µM (500ng/µL). The working stock is diluted 1:5 in Rnase-free dH2O to 20µM (100ng/µL).
+RT master mix
2µL
2µL
1µL
1µL
1µL
-----

no RT master mix
Buffer RT
2µL
5mM dNTPs
2µL
20uM random Hexomers
1µL
10u/µL Rnase inhibitor
1µL
Omniscript RT
----dH20 (Rnase-free)
1µL

-Vortex master mixes and spin down. Place on ice until ready.
-Add 7µL master mix to appropriate tubes (+ and – RT) – change tips in between samples! Final
volume of reaction = 20µL
-Incubate at 37C for 1 hour in thermocycler (make sure to put a +4C forever step at end)
(Can stop here and leave cDNA at +4C for a day or two, do not store in freezer!!)

qRT-PCR (using SYBR GREEN) – Fuss lab
Before setting up your experiment, need to optimize primers:
Note: Primer design: generate a ~100bp product
Fluorescence with SYBR green has a linear relationship with DNA mass (make sure primers
comparing generate same size product!! – or very similar)
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1.
2.

To determine annealing temp. of primers: use end-point PCR (+ and - RT) and run on
agarose gel
To determine primer efficiency: Run standard curve – Use dilution series using RNA with
known expression: 2ng, 20ng, 200ng, 2ug
-The difference in the primer efficiency between the gene of interest and endogenous
control primer set should not exceed 5%
(More info under analysis section)

Setup:
1.
Make cDNA from RNA
We use Sensiscript RT kit (Qiagen) for small amounts of RNA (up to 50ng) and
SuperscriptII (Invitrogen) for more than that
-Determine amount of RNA to be used for your experiment from dilution series of primers
-Make enough to run duplicates of both +RT and no RT control (a single no RT control
can also be run)
-Add same amount of RNA to each cDNA reaction
-Ex. If using 2ng RNA per reaction and running 3 primers you will need 12ng RNA (2ng
x2duplicates x3primers) so start with about 20ng RNA for your + and –RT reactions
2.

Making the SYBR green master mix:
-The number of master mixes to make is the number of primers running
-Make one master mix for one primer set for all samples to be run with that primer; cDNA
will be added directly to wells separately after
-Make 10% extra of master mix
Ex. If have 4 samples to be run in duplicates, then will need to make a master mix for 8
wells: multiply each master mix component by 8.8 (make 10% extra so do not come
short). This is done for each primer
SYBR green master mix comes as a 2X mix. (BioRad)
Each reaction is 50µl total volume
Master mix recipe for single reaction: multiply all reagents by x8.8 (from example above)
(a separate master mix needs to be made for each set of primers )
SYBR green mix
Forward primer
Reverse primer
ddH2O (do not use DEPC!)
cDNA*

25µl
x ul (0.15uM final)
x ul (0.15uM final)
x ul
x ul
50 ul total (look at example **)
*cDNA is not added to supermix, it is added to wells separately after master mix but need
to calculate its volume into the mix to determine how much ddH2O to add to get to a
total volume of 50 ul
**ex. If concentration of RNA used for cDNA reaction is 1ug/ul and using 2ng per
reaction, then 2ul of cDNA will need to be added per well and the total volume of the
master mix will be 48ul - that is the volume of master mix to be pipetted into wells.
NOTE: It is suggested to add cDNA to master mixes for better reproducibility, but this
requires making a master mix for each sample – this is a lot of work depending on how
many samples you have. We have had great reproducibility with duplicate samples by
pipetting cDNA directly into the wells and chose to continue to do it this way.
-Add master mix and samples to appropriate wells in strip
1.
Number the tube strips first so that you do not mix them up!!
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2.
3.
4.

Add master mix to appropriate wells in tube strips (48ul using example
from above**)
Add cDNA to appropriate wells separately– (change tips for each well!)
(add 2ul using example from above**)
Put strip caps on tubes and spin to collect liquid at bottom

-Protocol setup menu: Click “edit”
Adjust conditions as necessary
Cycles:
95C 15min
94C 15sec
XC 20sec – annealing temp variable - depends on primers using
72C 20sec
Read Plate
Go to line #2 x 34
Melting curve 70C to 90C
END
No need to put a 4C step at end!!
Make sure that reaction volume = 50ul (top right of screen)
-When done setting up, put sample strips into thermocycler in Karen’s room and use
metal “thing” to push down all caps and make sure they are tightly on

4.

Analysis
-To compare single gene expression between different samples, analyze using the
comparative Ct method - remember that to run this analysis method, the difference in the
primer efficiency between the gene of interest and the endogeneous control primer set
should not exceed 5%)
Set fluorescence threshold to where all sample amplification curves are in their linear
(exponential phase) and record their CT values at this threshold. Do not move the
threshold while recording numbers. Note: the threshold value can be recorded and reused if desired; the value is located in the quantitation section on the right side under the
threshold.
Equation: (note CT value is inversely proportional to expression)
∆CT (Control sample) = (CT experimental gene) – (CT endogeneous control gene)
∆CT (Experimental sample) = (CT experimental gene) – (CT endogeneous control
gene)
∆∆CT = ∆CT (Control sample) - ∆CT (experimental sample)
∆∆CT
0
2
= fold increase or decrease of control (control will be 1; 2 = 1)
Refer to: Livak KJ and Schmittgen TD 2001. Analysis of relative gene expression
data using real-time quantitative PCR and the 2(-Delta Delta C(T)) method. Methods.
-Comparing expression of different genes within a single sample
Need primer efficiencies for this calculation since we are using the same sample for
the comparison, endogeneous normalizing controls do not need to be run (read below
under section “determining primer efficiencies”
Equation rationale:
-CT
Ro = RCT x (1+E)
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Ro = starting fluorescence (proportional to starting template quantity)
RCT = Fluorescence at cycle CT is same for all samples so becomes a constant
E = Primer efficiency (100% = 1)
CT = Cycle at threshold T
-CT

Final equation to use: Ro = (1+E)
Compare Ro values from all different primers
Refer to: Peirson, et. al. 2003. Experimental validation of novel and conventional
approaches to quantitative real-time PCR data analysis. Nucleic acids research.
-Determining Primer efficiencies: (100% efficiency is doubling of product)
If did not already specify standards and their quantities when setting up protocol, go to
“master” and do it there.
Under quantification menu, select wells that are standards. To the right of the plate click
“manage” and then select all wells using for curve and name it and exit. Select that
newly made group then above quantitation curve, select log scale and move smooth all
the way to the left.
There is a graph to the right that will show Ct vs. log RNA. Toggle axis so the x-axis is
the log RNA and y-axis is the Ct. An equation will be displayed in form of y = mx + b
2
(m = slope); R value is also displayed which is a statistical term that says how good one
2
2
value is a predicting another value; if R = 1 then it is perfect; R value > 99% is good
Plug in slope into equation: Efficiency = 10

(-1/slope)

–1

(refer to website: http://www.uic.edu/depts/rrc/cgf/realtime/data.html)
Note: a 10-fold difference in sample is shown as 3.3 cycles in the log scale
3.3
(log2 10 = 3.3 or 2 = 10)
A slope of -3.3 in the graph (x-axis: log quantity; y-axis: Ct value) = 100% efficiency
because every 3.3 cycles is a 10-fold (or log quantity of 1) change; slope = -3.3/1
Note: recommended efficiency is between 90-100% and the slope between -3.1 and -3.6
-Comparing how much material between samples using Ct values:
3.3
Every 3.3 cycles is a 10-fold difference; log2 10 = 3.3 or 2 = ~10; log2 100 = 6.6 or
6.6
2 = ~100
-Comparing different runs:
-CT values generated from two different amplification runs can be directly compared only
if an identical FT (fluorescent threshold) is used for each run
-FT must be fixed if data from multiple runs are to be directly compared
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Reagents/Supplies needed:
§

Reverse transcriptase of choice - We use: Sensiscript (Qiagen #205211) – up to 50ng
SuperscriptII (Invitrogen #18064-014)
(Not included in the RT kits: you will also need an RNase inhibitor and either an OligodT
primer or random primers)

§

SYBR green mix of choice - We use: BioRad iQ Supermix #170-8882

§

Forward and Reverse Primers for both experimental and control genes (~100bp product)

§

ddH2O autoclaved (not DEPC!)

§

Flat cap strips – BioRad #TCS0803

§

Low tube strips, white – BioRad #TLS0851

§

qPCR machine

Other considerations:
§
§
§

Use filter-barrier pipette tips
It is best to dilute template to between 2-10ul to avoid inaccuracies in pipetting low
volumes
Mix all reagents well prior to making reaction mixes (inversion then quick spin)

Helpful reference papers:
§ Nolan et. al. 2006. Quantification of mRNA using real-time PCR. Nature Protocols.
§ Rutledge and Cote 2003. Mathematics of quantitative kinetic PCR and the application of
standard curves. Nucleic Acids Research.
Helpful websites:
§ http://www.uic.edu/depts/rrc/cgf/realtime/data.html
§ http://pathmicro.med.sc.edu/pcr/realtime-home.htm
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Figure 6.7: Inhibition of CaMKII by alters the expression of oligodendrocyte
myelin markers but not developmental transcription factors. Inhibition with either
KN-93 or MyrAIP decreases the expression of mbp, early expression exon 2
containing mbp, and PLP. However, there is no statistical reduction of the
transcription factor olig2. Black bar =100% of control values. N=3. Oneway
ANOVA P< 0.05
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Knocking out CaMKIIβ alters myelin thickness but not over all numbers of
myelinated axons or numbers of myelinated axons based on diameter in
the ventral spinal cord.
Camk2b-/- and Camk2bA303R mice (both in the F2 129P2-C57BL/6 background;
van Woerden et al., 2009; Borgesius et al., 2011) were generated and bred at
Erasmus University Medical Center. Spinal cord tissue was prepared and
analyzed by light microscopy as previously described (Dupree et al., 1998,
Marcus et al., 2006, Forrest et al., 2009). Used Nikon scope with 100x objective
and imaged 4 different fields of view in the ventral spinal cord per animal per
conditon. Used Image J to calcualte caliber and circularity.
Protocol for determining axon caliber and circularity using Image J
1. Open image in Imag J
2. Make it an 8-bit (image, type, 8-bit)
3. Threshold (contol, shift, T) ths is automatic threshold (works for most images
you can alter it form here if you want
4.Set image to ive you area and Curcularity (analyse, set mesurments, click area
and cirularity).
5.Set meusments for analysis (Analyze, Analyze Particles
a. Min sixe: 46 pix (ciricle w/1µm diameter)
b. Show: chose Outlines
c. click Display resutls
d. click exlcutde edge particles
6. in your result box click edit, copy all
7. Paste this into excel
8. Delete all axons with a circularity of less than 0.4: Circularity should have
come out as the C column ( A column is axon #, B column is Area) when you
pasted the results into excel. Highlight that column click ‘sort ascending’ (AZê
box next to the Sigma sign), then delete all axons until you hit 0.4 circularity
9. Discount any ‘red areas’ that are not really axons that Image J picked up
finding the corresponding axon# on the ‘outlines’ windo. Once you have already
remove all axons the circularity less than0.4, highlight column A and click ‘sort
ascending’. Now you can delete the corresponding axons you did not wan to be
counted.
Converting area (pixels to Diameter (µm)
Area (pixels
Diameter
46-183
1-1.9
184-413
2-2.9
414-782
3-3.9
783-1150
4-4.9
1151-1796
5-5.9
1797- 2442
6-6.9
2443-3088
7-7.9
3089-3734
8-8.9
3734 +
9+
153

Figure 6.8: There is no statistical difference in the number of myelinated axons
based on axon diameter after knock out of CaMKIIβ at a young or adult age. A.
P21 camk2b-/- mice show no statistical difference in the number of myelinated
axons when grouped by axon size. There is a trend towards a loss of large
diameter axons in the KO group; however, this is not statistically significant. B.
Same results seen in juvenile as in adult 56 day old mice that here is no total loss
or loss based on axon diameter. C. Camk2bA303R mice show no difference in
myelinated axon number when ca2+/ calmodulin is unable to bind allowing this to
be a catalytically altered mutant.
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